Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1623kxg

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	APR 04	STN AnaVist, Version 1, to be discontinued
NEWS 3	APR 15	WPIDS, WPINDEX, and WPIX enhanced with new predefined hit display formats
NEWS 4	APR 28	EMBASE Controlled Term thesaurus enhanced
NEWS 5	APR 28	IMSRESEARCH reloaded with enhancements
NEWS 6	MAY 30	INPAFAMDB now available on STN for patent family searching
NEWS 7	MAY 30	DGENE, PCTGEN, and USGENE enhanced with new homology sequence search option
NEWS 8	JUN 06	EPFULL enhanced with 260,000 English abstracts
NEWS 9	JUN 06	KOREAPAT updated with 41,000 documents
NEWS 10	JUN 13	USPATFULL and USPAT2 updated with 11-character patent numbers for U.S. applications
NEWS 11	JUN 19	CAS REGISTRY includes selected substances from web-based collections
NEWS 12	JUN 25	CA/CAplus and USPAT databases updated with IPC reclassification data
NEWS 13	JUN 30	AEROSPACE enhanced with more than 1 million U.S. patent records
NEWS 14	JUN 30	EMBASE, EMBAL, and LEMBASE updated with additional options to display authors and affiliated organizations
NEWS 15	JUN 30	STN on the Web enhanced with new STN AnaVist Assistant and BLAST plug-in
NEWS 16	JUN 30	STN AnaVist enhanced with database content from EPFULL
NEWS 17	JUL 28	CA/CAplus patent coverage enhanced
NEWS 18	JUL 28	EPFULL enhanced with additional legal status information from the epoline Register
NEWS 19	JUL 28	IFICDB, IFIPAT, and IFIUDB reloaded with enhancements
NEWS 20	JUL 28	STN Viewer performance improved
NEWS 21	AUG 01	INPADOCDB and INPAFAMDB coverage enhanced
NEWS 22	AUG 13	CA/CAplus enhanced with printed Chemical Abstracts page images from 1967-1998
NEWS 23	AUG 15	CAOLD to be discontinued on December 31, 2008
NEWS 24	AUG 15	CAplus currency for Korean patents enhanced
NEWS 25	AUG 25	CA/CAplus, CASREACT, and IFI and USPAT databases enhanced for more flexible patent number searching
NEWS 26	AUG 27	CAS definition of basic patents expanded to ensure comprehensive access to substance and sequence information

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS STN Operating Hours Plus Help Desk Availability

```
 NEWS LOGIN    Welcome Banner and News Items
 NEWS IPC8     For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 17:36:45 ON 13 SEP 2008

=> file polymer medline embase biosis
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.21       0.21

FILE 'APOLLIT' ENTERED AT 17:37:11 ON 13 SEP 2008
COPYRIGHT (c) 2008 FIZ Karlsruhe

FILE 'BABS' ENTERED AT 17:37:11 ON 13 SEP 2008
COPYRIGHT (c) 2008 Beilstein-Institut zur Foerderung der Chemischen Wissenschaften
licensed to Beilstein Chemiedaten & Software GmbH and MDL Information Systems GmbH

FILE 'CAPLUS' ENTERED AT 17:37:11 ON 13 SEP 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CBNB' ENTERED AT 17:37:11 ON 13 SEP 2008
COPYRIGHT (c) 2008 ELSEVIER ENGINEERING INFORMATION, INC.

FILE 'CIN' ENTERED AT 17:37:11 ON 13 SEP 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

FILE 'COMPENDEX' ENTERED AT 17:37:11 ON 13 SEP 2008
Compendex Compilation and Indexing (C) 2008
Elsevier Engineering Information Inc (EEI). All rights reserved.
Compendex (R) is a registered Trademark of Elsevier Engineering Information Inc.

FILE 'DISSABS' ENTERED AT 17:37:11 ON 13 SEP 2008
COPYRIGHT (C) 2008 ProQuest Information and Learning Company; All Rights Reserved.

FILE 'EMA' ENTERED AT 17:37:11 ON 13 SEP 2008
COPYRIGHT (C) 2008 Cambridge Scientific Abstracts (CSA)

FILE 'IFIPAT' ENTERED AT 17:37:11 ON 13 SEP 2008
COPYRIGHT (C) 2008 IFI CLAIMS(R) Patent Services (IFI)

FILE 'NTIS' ENTERED AT 17:37:11 ON 13 SEP 2008
Compiled and distributed by the NTIS, U.S. Department of Commerce.
It contains copyrighted material.
All rights reserved. (2008)

FILE 'PASCAL' ENTERED AT 17:37:11 ON 13 SEP 2008
Any reproduction or dissemination in part or in full,
```

FILE 'PROMT' ENTERED AT 17:37:11 ON 13 SEP 2008

FILE 'RAPRA' ENTERED AT 17:37:11 ON 13 SEP 2008

FILE 'SCISEARCH' ENTERED AT 17:37:11 ON 13 SEP 2008

FILE 'TEXTILETECH' ENTERED AT 17:37:11 ON 13 SEP 2008

FILE 'USPATFULL' ENTERED AT 17:37:11 ON 13 SEP 2008

FILE 'USPATOLD' ENTERED AT 17:37:11 ON 13 SEP 2008

FILE 'USPAT2' ENTERED AT 17:37:11 ON 13 SEP 2008

FILE 'WPIDS' ACCESS NOT AUTHORIZED

FILE 'WPIFV' ENTERED AT 17:37:11 ON 13 SEP 2008

FILE 'WPINDEX' ENTERED AT 17:37:11 ON 13 SEP 2008

FILE 'WSCA' ENTERED AT 17:37:11 ON 13 SEP 2008

FILE 'WTEXTILES' ENTERED AT 17:37:11 ON 13 SEP 2008

FILE 'MEDLINE' ENTERED AT 17:37:11 ON 13 SEP 2008

FILE 'EMBASE' ENTERED AT 17:37:11 ON 13 SEP 2008

FILE 'BIOSIS' ENTERED AT 17:37:11 ON 13 SEP 2008


```
=> s glucosamine or N-acetyl glucosamine or galactosamine
L1      126804 GLUCOSAMINE OR N-ACETYL GLUCOSAMINE OR GALACTOSAMINE

=> s l1 and (cartilage(a)degrad?) or synovitis or (subchondral(a)bone (a)edema)
  21 FILES SEARCHED...
L2       36190 L1 AND (CARTILAGE(A) DEGRAD?) OR SYNOVITIS OR (SUBCHONDRAL(A)
               BONE (A) EDEMA)

=> s l2 and treat?
  20 FILES SEARCHED...
L3       14398 L2 AND TREAT?

=> s l3 and (matrix or particle or gel or implant)
  17 FILES SEARCHED...
L4        4305 L3 AND (MATRIX OR PARTICLE OR GEL OR IMPLANT)
```

```
=> s l4 and (anti(a)inflammatory(a)drug) or hexoaminidase
  24 FILES SEARCHED...
L5        1629 L4 AND (ANTI(A) INFLAMMATORY(A) DRUG) OR HEXOAMINIDASE

=> s l5 and glucosamine
L6         268 L5 AND GLUCOSAMINE

=> s l6 and (subchondral(a)bone(a)edema)
L7           6 L6 AND (SUBCHONDRAL(A) BONE(A) EDEMA)

=> dis l7 1-6 bib abs

L7   ANSWER 1 OF 6  IFIPAT  COPYRIGHT 2008 IFI on STN
AN    11492254  IFIPAT;IFIUDB;IFICDB
TI    Treatment of a condition in a mammal with administration of
      aminosugar and uses thereof
INF   SHUE; Youe-Kong, Carlsbad, CA, US
IN    SHUE Youe-Kong
PAF   Unassigned
PA    Unassigned Or Assigned To Individual (68000)
PPA   Optimer Pharmaceuticals Inc (Probable)
AG    CATALYST LAW GROUP, APC, 9710 SCRANTON ROAD, SUITE S-170, SAN DIEGO, CA,
      92121, US
PI    US 20070142326  A1  20070621
AI    US 2004-574054      20040930
      WO 2004-US32048     20040930
                          20060607  PCT 371 date
                          20060607  PCT 102(e) date
FI    US 20070142326      20070621
DT    Utility; Patent Application - First Publication
FS    CHEMICAL
      APPLICATION
ED    Entered STN: 22 Jun 2007
      Last Updated on STN: 17 Jul 2007
GOVI  This invention was made in part with United States government support
      under grant number NIH AG 07996 and AT 00052 awarded by the National
      Institutes of Health. The U.S. Government may have certain rights in this
      invention.
PARN  This application claims priority from Provisional Patent Application No.
      60/507,716 filed on Oct. 1, 2003, entitled TREATMENT OF A
      CONDITION IN A MAMMAL WITH ADMINISTRATION OF AMINOSUGAR AND USES THEREOF.
CLMN  33
GI     8 Figure(s).
     FIG. 1A shows the gross morphological grading of femoral condyles in
      rabbits with bilateral anterior cruciate ligament transection (ACLT) and
      treated with intramuscular GlcNAc or normal saline.
     FIG. 1B shows the gross morphological grading of tibial plateau in rabbits
      with bilateral anterior cruciate ligament (ACL) transection and
      treated with intra-muscular GlcNAc or normal saline.
     FIG. 2 shows the gross morphological grading of femoral condyles in
      rabbits with unilateral ACL transection and treated with
      intra-articular GlcNAc, Sodium hyaluronate or saline.
     FIG. 3 shows the gross morphological grading of tibial plateaus in rabbits
      with unilateral ACL transection and treated with
      intra-articular GlcNAc, Sodium hyaluronate or saline.
     FIG. 4 illustrates the gross morphological assessment of joint swelling in
      rabbits with unilateral ACL transection and treated with
      intra-articular GlcNAc, Sodium hyaluronate or saline.
     FIG. 5 illustrates DNA content in synovial tissue from rabbits with
      unilateral ACL transection and treated with intra-articular
      GlcNAc, Sodium hyaluronate or saline.
```

FIG. 6 shows the digital image analysis of the lesion size in femoral condyles (FIG. 6A) and tibial plateaus (FIG. 6B) from rabbits with unilateral ACL transection and treated with intra-articular GlcNAc or Sodium hyaluronate.

FIG. 7 shows the time dependant in vitro release of GlcNAc entrapped in injectable polymeric formulations according to one embodiment of the present inventions.

OF 6 IFIPAT COPYRIGHT 2008 IFI on STN

AB The present invention relates to treating joint related conditions in mammals by administering an aminosugar, and wherein said treatment specifically prevents, lessens or reverses pathologies associated with the joint condition, said pathologies being selected from the group consisting of synovitis, subchondral bone edema, and cartilage degradation .

CLMN 33 8 Figure(s).

FIG. 1A shows the gross morphological grading of femoral condyles in rabbits with bilateral anterior cruciate ligament transection (ACLT) and treated with intramuscular GlcNAc or normal saline.

FIG. 1B shows the gross morphological grading of tibial plateau in rabbits with bilateral anterior cruciate ligament (ACL) transection and treated with intra-muscular GlcNAc or normal saline.

FIG. 2 shows the gross morphological grading of femoral condyles in rabbits with unilateral ACL transection and treated with intra-articular GlcNAc, Sodium hyaluronate or saline.

FIG. 3 shows the gross morphological grading of tibial plateaus in rabbits with unilateral ACL transection and treated with intra-articular GlcNAc, Sodium hyaluronate or saline.

FIG. 4 illustrates the gross morphological assessment of joint swelling in rabbits with unilateral ACL transection and treated with intra-articular GlcNAc, Sodium hyaluronate or saline.

FIG. 5 illustrates DNA content in synovial tissue from rabbits with unilateral ACL transection and treated with intra-articular GlcNAc, Sodium hyaluronate or saline.

FIG. 6 shows the digital image analysis of the lesion size in femoral condyles (FIG. 6A) and tibial plateaus (FIG. 6B) from rabbits with unilateral ACL transection and treated with intra-articular GlcNAc or Sodium hyaluronate.

FIG. 7 shows the time dependant in vitro release of GlcNAc entrapped in injectable polymeric formulations according to one embodiment of the present inventions.

L7 ANSWER 2 OF 6 IFIPAT COPYRIGHT 2008 IFI on STN

AN 11432795 IFIPAT;IFIUDB;IFICDB

TI Treatment of a condition in a mammal with administration of Compounds and Methods of Use

INF Ichikawa; Yoshitaka, San Diego, CA, US

IN Ichikawa Yoshitaka

PAF Optimer Pharmaceuticals Inc., San Diego, CA, US
The Scripps Research Institute, La Jolla, CA, US

PA Scripps Research Institute The (29999)

AG CATALYST LAW GROUP, APC, 9710 SCRANTON ROAD, SUITE S-170, SAN DIEGO, CA, 92121, US

PI US 20070082851 A1 20070412

AI US 2004-580512 20041123
WO 2004-US39680 20041123
20060523 PCT 371 date
20060523 PCT 102(e) date

PRAI US 2003-524698P 20031124 (Provisional)

FI US 20070082851 20070412

DT Utility; Patent Application - First Publication

FS CHEMICAL

APPLICATION
ED Entered STN: 13 Apr 2007
Last Updated on STN: 7 May 2007
PARN This application claims the benefit of U.S. provisional application Ser. No. 60/524,698, filed on Nov. 24, 2003, which is hereby incorporated in its entirety by reference.
CLMN 92
OF 6 IFIPAT COPYRIGHT 2008 IFI on STN
AB This invention relates to methods of treating, preventing, and lessening the severity of conditions or diseases selected from the group consisting of osteoarthritis (OA), rheumatoid arthritis, synovitis, subchondral bone edema, and cartilage degradation ("OA and related disorders") with administration of an aminosugar derivative and pharmaceutically acceptable salts thereof.
CLMN 92

L7 ANSWER 3 OF 6 USPATFULL on STN
AN 2007:225371 USPATFULL
TI Treatment of degenerative cartilage conditions in a mammal with Glycosidasc Inhibitors
IN Ichikawa, Yoshitaka, San DIego, CA, UNITED STATES
PA Optimer Pharmaceuticals, Inc., San Diego, CA, UNITED STATES, 92121 (U.S. corporation)
The Scripps Research Institute, LaJolla, CA, UNITED STATES, 92037 (U.S. corporation)
PI US 20070197471 A1 20070823
AI US 2005-586578 A1 20050120 (10)
WO 2005-US2017 20050120
20060925 PCT 371 date
PRAI US 2004-531168P 20040120 (60)
DT Utility
FS APPLICATION
LREP CATALYST LAW GROUP, APC, 9710 SCRANTON ROAD, SUITE S-170, SAN DIEGO, CA, 92121, US
CLMN Number of Claims: 42
ECL Exemplary Claim: 1
DRWN 3 Drawing Page(s)
LN.CNT 871
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to treating, preventing, and lessening the severity of conditions selected from the group consisting of osteoarthritis, rheumatoid arthritis, synovitis, subchondral bone edema, and cartilage degradation with administration of glycosidase inhibitors.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 4 OF 6 USPATFULL on STN
AN 2007:162770 USPATFULL
TI Treatment of a condition in a mammal with administration of aminosugar and uses thereof
IN SHUE, Youe-Kong, Carlsbad, CA, UNITED STATES
PI US 20070142326 A1 20070621
AI US 2004-574054 A1 20040930 (10)
WO 2004-US32048 20040930
20060607 PCT 371 date
DT Utility
FS APPLICATION
LREP CATALYST LAW GROUP, APC, 9710 SCRANTON ROAD, SUITE S-170, SAN DIEGO, CA, 92121, US

CLMN Number of Claims: 33
ECL Exemplary Claim: 1
DRWN 5 Drawing Page(s)
LN.CNT 1110
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to treating joint related conditions in mammals by administering an aminosugar, and wherein said treatment specifically prevents, lessens or reverses pathologies associated with the joint condition, said pathologies being selected from the group consisting of synovitis, subchondral bone edema, and cartilage degradation.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 5 OF 6 USPATFULL on STN
AN 2007:95149 USPATFULL
TI Treatment of a condition in a mammal with administration of Compounds and Methods of Use
IN Ichikawa, Yoshitaka, San Diego, CA, UNITED STATES
PA Optimer Pharmaceuticals Inc., San Diego, CA, UNITED STATES (U.S. corporation)
The Scripps Research Institute, La Jolla, CA, UNITED STATES (U.S. corporation)
PI US 20070082851 A1 20070412
AI US 2004-580512 A1 20041123 (10)
WO 2004-US39680 20041123
20060523 PCT 371 date
PRAI US 2003-524698P 20031124 (60)
DT Utility
FS APPLICATION
LREP CATALYST LAW GROUP, APC, 9710 SCRANTON ROAD, SUITE S-170, SAN DIEGO, CA, 92121, US
CLMN Number of Claims: 92
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2022
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to methods of treating, preventing, and lessening the severity of conditions or diseases selected from the group consisting of osteoarthritis (OA), rheumatoid arthritis, synovitis, subchondral bone edema, and cartilage degradation ("OA and related disorders") with administration of an aminosugar derivative and pharmaceutically acceptable salts thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 6 OF 6 WPINDEX COPYRIGHT 2008 THOMSON REUTERS on STN
AN 2005-306268 [31] WPINDEX
DNC C2005-094925 [31]
TI Treating a joint condition, e.g. subchondral bone edema, comprises administration of an amino sugar formulation
DC B03
IN LOTZ M; OKUMU F W; SHIKHMAN A R; SHUE Y; OKUMU F; SHIKHMAN A
PA (OPTI-N) OPTIMER PHARM; (OPTI-N) OPTIMER PHARM INC; (SHUE-I) SHUE Y
CYC 107
PIA WO 2005034961 A1 20050421 (200531)* EN 36[7]
EP 1670486 A1 20060621 (200643) EN
JP 2007507516 W 20070329 (200725) JA 24
US 20070142326 A1 20070621 (200741) EN

CN 1909911 A 20070207 (200743) ZH
ADT WO 2005034961 A1 WO 2004-US32048 20040930; EP 1670486 A1 EP 2004-789289 20040930; EP 1670486 A1 WO 2004-US32048 20040930; JP 2007507516 W WO 2004-US32048 20040930; US 20070142326 A1 WO 2004-US32048 20040930; JP 2007507516 W JP 2006-534068 20040930; US 20070142326 A1 US 2006-574054 20060607; CN 1909911 A CN 2004-80032374 20040930
FDT EP 1670486 A1 Based on WO 2005034961 A; JP 2007507516 W Based on WO 2005034961 A
PRAI US 2003-507716P 20031001
US 2006-574054 20060607
AN 2005-306268 [31] WPINDEX
AB WO 2005034961 A1 UPAB: 20051221
NOVELTY - Treating a joint condition comprises diagnosing a pathological marker associated with a joint condition and administering an amino sugar in a formulation.
DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for:
(1) treating synovitis, subchondral bone edema or cartilage degradation comprising administering an amino sugar;
(2) treating pathologies associated with a joint condition comprising administering N-acetylglucosamine as a controlled release formulation; and
(3) an injectable formulation comprising an aminosugar, which is entrapped by a matrix, where the matrix comprises a particle, implant or gel.
ACTIVITY - Osteopathic; Antiinflammatory.
Rabbits having bilateral anterior cruciate ligament transection (ACLT) were injected intra-articular injection of N-acetylgalactosamine (0.3 ml) (test compound) two times per week for a total of 7 weeks. Synovial fluid analysis was performed in animals that developed gross synovial effusions. The test compound showed improvement in the condition of the tibial plateaus and femoral condyles. The gross morphological analysis of the femoral condyles demonstrated a trend towards improved cartilage condition (improved lesions) (in terms of mild swelling) for the test group. The gross morphological analysis of the tibial plateaus revealed remarkable chondroprotective activity of the test compound (where 1 - 7 treatment rabbits developed a cartilage lesion) (in terms of mild effusion).
MECHANISM OF ACTION - None given.
USE - For the treatment of pathology associated with a joint condition which is not osteoarthritis, rheumatoid arthritis in a mammal e.g. synovitis, subchondral bond edema and cartilage degradation (all claimed).
ADVANTAGE - The formulation prevents cartilage degradation. The formulation prevents, lessen or reverse many of the pathological markers associated with joint conditions such as synovitis; provides improved biocompatibility and biodegradability.

=> l6 and synovitis
L6 IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> s l6 and synovitis
L8 204 L6 AND SYNOVITIS

=> s l5 and synovitis
L9 1371 L5 AND SYNOVITIS

```
=> s l9 and intra(a)articular
L10        305 L9 AND INTRA(A) ARTICULAR

=> s l9 and inject?
L11       1266 L9 AND INJECT?

=> s l10 and inject?
L12        295 L10 AND INJECT?

=> s glucosamine
L13     102103 GLUCOSAMINE

=> s l13 and synovitis
L14        458 L13 AND SYNOVITIS

=> s l14 and intra(a)articular
L15        100 L14 AND INTRA(A) ARTICULAR

=> s l15 and inject?
L16         79 L15 AND INJECT?

=> s l16 and (gel or implant or matrix or particle)
  22 FILES SEARCHED...
L17         73 L16 AND (GEL OR IMPLANT OR MATRIX OR PARTICLE)

=> dis l17 1-73 bib abs

L17  ANSWER 1 OF 73  IFIPAT  COPYRIGHT 2008 IFI on STN
AN    11492254  IFIPAT;IFIUDB;IFICDB
TI    Treatment of a condition in a mammal with administration of aminosugar
      and uses thereof
INF   SHUE; Youe-Kong, Carlsbad, CA, US
IN    SHUE Youe-Kong
PAF   Unassigned
PA    Unassigned Or Assigned To Individual (68000)
PPA   Optimer Pharmaceuticals Inc (Probable)
AG    CATALYST LAW GROUP, APC, 9710 SCRANTON ROAD, SUITE S-170, SAN DIEGO, CA,
      92121, US
PI    US 20070142326  A1  20070621
AI    US 2004-574054      20040930
      WO 2004-US32048     20040930
                          20060607  PCT 371 date
                          20060607  PCT 102(e) date
FI    US 20070142326      20070621
DT    Utility; Patent Application - First Publication
FS    CHEMICAL
      APPLICATION
ED    Entered STN: 22 Jun 2007
      Last Updated on STN: 17 Jul 2007
GOVI  This invention was made in part with United States government support
      under grant number NIH AG 07996 and AT 00052 awarded by the National
      Institutes of Health. The U.S. Government may have certain rights in this
      invention.
PARN  This application claims priority from Provisional Patent Application No.
      60/507,716 filed on Oct. 1, 2003, entitled TREATMENT OF A CONDITION IN A
      MAMMAL WITH ADMINISTRATION OF AMINOSUGAR AND USES THEREOF.
CLMN  33
GI     8 Figure(s).
     FIG. 1A shows the gross morphological grading of femoral condyles in
      rabbits with bilateral anterior cruciate ligament transection (ACLT) and
      treated with intramuscular GlcNAc or normal saline.
     FIG. 1B shows the gross morphological grading of tibial plateau in rabbits
```

with bilateral anterior cruciate ligament (ACL) transection and treated with intra-muscular GlcNAc or normal saline.
FIG. 2 shows the gross morphological grading of femoral condyles in rabbits with unilateral ACL transection and treated with intra-articular GlcNAc, Sodium hyaluronate or saline.
FIG. 3 shows the gross morphological grading of tibial plateaus in rabbits with unilateral ACL transection and treated with intra-articular GlcNAc, Sodium hyaluronate or saline.
FIG. 4 illustrates the gross morphological assessment of joint swelling in rabbits with unilateral ACL transection and treated with intra-articular GlcNAc, Sodium hyaluronate or saline.
FIG. 5 illustrates DNA content in synovial tissue from rabbits with unilateral ACL transection and treated with intra-articular GlcNAc, Sodium hyaluronate or saline.
FIG. 6 shows the digital image analysis of the lesion size in femoral condyles (FIG. 6A) and tibial plateaus (FIG. 6B) from rabbits with unilateral ACL transection and treated with intra-articular GlcNAc or Sodium hyaluronate.
FIG. 7 shows the time dependant in vitro release of GlcNAc entrapped in injectable polymeric formulations according to one embodiment of the present inventions.

OF 73 IFIPAT COPYRIGHT 2008 IFI on STN

AB The present invention relates to treating joint related conditions in mammals by administering an aminosugar, and wherein said treatment specifically prevents, lessens or reverses pathologies associated with the joint condition, said pathologies being selected from the group consisting of synovitis, subchondral bone edema, and cartilage degradation.

CLMN 33 8 Figure(s).

FIG. 1A shows the gross morphological grading of femoral condyles in rabbits with bilateral anterior cruciate ligament transection (ACLT) and treated with intramuscular GlcNAc or normal saline.
FIG. 1B shows the gross morphological grading of tibial plateau in rabbits with bilateral anterior cruciate ligament (ACL) transection and treated with intra-muscular GlcNAc or normal saline.
FIG. 2 shows the gross morphological grading of femoral condyles in rabbits with unilateral ACL transection and treated with intra-articular GlcNAc, Sodium hyaluronate or saline.
FIG. 3 shows the gross morphological grading of tibial plateaus in rabbits with unilateral ACL transection and treated with intra-articular GlcNAc, Sodium hyaluronate or saline.
FIG. 4 illustrates the gross morphological assessment of joint swelling in rabbits with unilateral ACL transection and treated with intra-articular GlcNAc, Sodium hyaluronate or saline.
FIG. 5 illustrates DNA content in synovial tissue from rabbits with unilateral ACL transection and treated with intra-articular GlcNAc, Sodium hyaluronate or saline.
FIG. 6 shows the digital image analysis of the lesion size in femoral condyles (FIG. 6A) and tibial plateaus (FIG. 6B) from rabbits with unilateral ACL transection and treated with intra-articular GlcNAc or Sodium hyaluronate.
FIG. 7 shows the time dependant in vitro release of GlcNAc entrapped in injectable polymeric formulations according to one embodiment of the present inventions.

L17 ANSWER 2 OF 73 USPATFULL on STN

AN 2008:239009 USPATFULL

TI Novel Compounds 569

IN Connolly, Stephen, Loughborough, UNITED KINGDOM
Humphries, Alexander, Loughborough, UNITED KINGDOM
Meghani, Premji, Loughborough, UNITED KINGDOM

PI US 20080207698 A1 20080828

AI US 2007-959679 A1 20071219 (11)
PRAI US 2007-951980P 20070726 (60)
US 2007-910045P 20070404 (60)
US 2006-870922P 20061220 (60)
DT Utility
FS APPLICATION
LREP FISH & RICHARDSON P.C., P.O BOX 1022, MINNEAPOLIS, MN, 55440-1022, US
CLMN Number of Claims: 18
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 4637
AB The present invention provides compounds of formula (I)

##STR1##

wherein R.sup.a, R.sup.b, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6 and R.sup.29 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.

L17 ANSWER 3 OF 73 USPATFULL on STN
AN 2008:227342 USPATFULL
TI COMPOUNDS
IN Barker, Wendy, Macclesfield, UNITED KINGDOM
Keyes, Fenagh Anne, Cambridge, UNITED KINGDOM
PA ASTRAZENECA AB, Sodertalje, SWEDEN (non-U.S. corporation)
PI US 20080199481 A1 20080821
AI US 2008-33145 A1 20080219 (12)
PRAI US 2007-890888P 20070221 (60)
US 2007-908041P 20070326 (60)
DT Utility
FS APPLICATION
LREP ASTRAZENECA R&D BOSTON, 35 GATEHOUSE DRIVE, WALTHAM, MA, 02451-1215, US
CLMN Number of Claims: 66
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 4314
AB The present invention relates to binding members, especially antibody molecules, for CXCL13. The binding members are useful for the treatment of disorders associated with CXCL13, including arthritic disorders such as rheumatoid arthritis.

L17 ANSWER 4 OF 73 USPATFULL on STN
AN 2008:213877 USPATFULL
TI TREATING AND EVALUATING INFLAMMATORY DISORDERS
IN Burkly, Linda C., West Newton, MA, UNITED STATES
Zheng, Timothy, Boston, MA, UNITED STATES
PI US 20080187544 A1 20080807
AI US 2007-937687 A1 20071109 (11)
RLI Continuation of Ser. No. WO 2006-US18077, filed on 10 May 2006, PENDING
PRAI US 2005-679518P 20050510 (60)
DT Utility
FS APPLICATION
LREP BIOGEN IDEC / FINNEGAN HENDERSON, LLP, 901 NEW YORK AVENUE, NW, WASHINGTON, DC, 20001-4413, US
CLMN Number of Claims: 54
ECL Exemplary Claim: 1
DRWN 8 Drawing Page(s)
LN.CNT 2494
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods of treating inflammatory disorders, such as rheumatoid arthritis, by modulating TWEAK and TNF-α are disclosed, as are other methods.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 5 OF 73 USPATFULL on STN
AN 2008:182832 USPATFULL
TI Macromolecular Delivery Systems for Non-Invasive Imaging, Evaluation and Treatment of Arthritis and Other Inflammatory Diseases
IN Wang, Dong, Omaha, NE, UNITED STATES
Kopecek, Jindrich, Salt Lake City, UT, UNITED STATES
Miller, Scott C., Salt Lake City, UT, UNITED STATES
Kopeckova, Pavla, Salt Lake City, UT, UNITED STATES
PA University of Utah Research Foundation, Salt Lake City, UT, UNITED STATES (U.S. corporation)
PI US 20080159959 A1 20080703
AI US 2005-591258 A1 20050330 (10)
WO 2005-US10801 20050330
20061128 PCT 371 date
PRAI US 2004-558047P 20040331 (60)
DT Utility
FS APPLICATION
LREP Needle and Rosenberg, 999 Peachtree Street, Suite 1000, Atlanta, GA, 30309, US
CLMN Number of Claims: 65
ECL Exemplary Claim: 1
DRWN 10 Drawing Page(s)
LN.CNT 1303
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to biotechnology, more particularly, to water-soluble polymeric delivery systems for the imaging, evaluation and/or treatment of rheumatoid arthritis and other inflammatory diseases. Using modern MR imaging techniques, the specific accumulation of macromolecules in arthritic joints in adjuvant-induced arthritis in rats is demonstrated. The strong correlation between the uptake and retention of the MR contrast agent labeled polymer with histopathological features of inflammation and local tissue damage demonstrates the practical applications of the macromolecular delivery system of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 6 OF 73 USPATFULL on STN
AN 2008:152205 USPATFULL
TI 5-Heteroaryl Thiazoles And Their Use As PI3K Inhibitors
IN Bengtsson, Malena, Lund, SWEDEN
Larsson, Joakim, Lund, SWEDEN
Nikitidis, Grigorios, Lund, SWEDEN
Storm, Peter, Molndal, SWEDEN
Bailey, John Peter, Cheshire, UNITED KINGDOM
Griffen, Edward Jolyon, Cheshire, UNITED KINGDOM
Arnould, Jean-Claude, Reims, FRANCE
Bird, Thomas Geoffrey Colerick, Reims, FRANCE
PI US 20080132502 A1 20080605
AI US 2005-667064 A1 20051107 (11)
WO 2005-GB4268 20051107
20070504 PCT 371 date
PRAI SE 2004-2735 20041109
DT Utility
FS APPLICATION
LREP MORGAN LEWIS & BOCKIUS LLP, 1111 PENNSYLVANIA AVENUE NW, WASHINGTON, DC,

20004, US
CLMN Number of Claims: 18
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 6860
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides thiazole derivatives of formula (I), or pharmaceutically acceptable salts thereof in which Ring A, R.sup.1, R.sup.2 and R.sup.3 are as defined in the specification; a processes for their preparation; pharmaceutical compositions containing them; and their use in therapy, for example in the treatment of disease mediated by a PI3K enzyme and/or a mTOR kinase.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 7 OF 73 USPATFULL on STN
AN 2008:66389 USPATFULL
TI Novel Compounds 171
IN Cheshire, David, Loughborough, UNITED KINGDOM
Guile, Simon, Loughborough, UNITED KINGDOM
Thompson, Toby, Loughborough, UNITED KINGDOM
PA ASTRAZENECA AB (non-U.S. corporation)
PI US 20080058309 A1 20080306
AI US 2007-828577 A1 20070726 (11)
PRAI US 2006-833675P 20060727 (60)
DT Utility
FS APPLICATION
LREP FISH & RICHARDSON P.C., P.O BOX 1022, MINNEAPOLIS, MN, 55440-1022, US
CLMN Number of Claims: 18
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2362
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides compounds of formula (I), processes for their preparation, pharmaceutical compositions containing them, a process for preparing the pharmaceutical compositions, and their use in therapy, wherein A, D, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, n, p and q are as defined in the specification. ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 8 OF 73 USPATFULL on STN
AN 2008:50671 USPATFULL
TI COMPOUNDS
IN Cochrane, Duncan, Cambridge, UNITED KINGDOM
Russell, Caroline, Cambridge, UNITED KINGDOM
Sleeman, Matthew, Cambridge, UNITED KINGDOM
Welsh, Fraser, Cambridge, UNITED KINGDOM
Langham, Caroline, Macclesfield, UNITED KINGDOM
Needham, Maurice, Macclesfield, UNITED KINGDOM
Dufner, Patrick, Zurich, SWITZERLAND
PI US 20080044423 A1 20080221
AI US 2007-767208 A1 20070622 (11)
PRAI US 2006-815828P 20060623 (60)
US 2007-913566P 20070424 (60)
DT Utility
FS APPLICATION
LREP COOLEY GODWARD KRONISH LLP, ATTN: Patent Group, Suite 1100, 777 - 6th Street, NW, WASHINGTON, DC, 20001, US
CLMN Number of Claims: 78
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)

LN.CNT 6938
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Binding members, especially antibody molecules, for interleukin 17 (IL-17). The binding members are useful for the treatment of disorders associated with interleukin 17 such as rheumatoid arthritis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 9 OF 73 USPATFULL on STN
AN 2008:23857 USPATFULL
TI Novel Piperidine/8-Azabicyclo [3.2.1.] Octan Derivatives As Modulators Of Chemokine Receptor Ccr5
IN Tucker, Howard, Macclesfield, UNITED KINGDOM
Faull, Alan, Macclesfield, UNITED KINGDOM
PI US 20080021038 A1 20080124
AI US 2005-628808 A1 20050620 (11)
WO 2005-SE953 20050620
20061207 PCT 371 date
PRAI SE 2004-1656 20040624
DT Utility
FS APPLICATION
LREP MORGAN LEWIS & BOCKIUS LLP, 1111 PENNSYLVANIA AVENUE NW, WASHINGTON, DC, 20004, US
CLMN Number of Claims: 16
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3749
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds of formula (I) wherein neither R.sup.4 nor R.sup.5 is hydrogen; compositions comprising them, processes for preparing them and their use in medical therapy (for example modulating CCR5 receptor activity in a warm blooded animal). ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 10 OF 73 USPATFULL on STN
AN 2008:5060 USPATFULL
TI Composition and Method for Treating Connective Tissue Damage by Transmucosal Administration
IN Marcum, Frank D., Versailles, KY, UNITED STATES
Seanor, John William, Lexington, KY, UNITED STATES
PI US 20080004238 A1 20080103
AI US 2007-766515 A1 20070621 (11)
RLI Continuation-in-part of Ser. No. US 2005-105163, filed on 13 Apr 2005, PENDING Continuation-in-part of Ser. No. US 2004-15137, filed on 17 Dec 2004, PENDING Continuation-in-part of Ser. No. US 2003-686918, filed on 16 Oct 2003, GRANTED, Pat. No. US 6979679
PRAI US 2003-487681P 20030716 (60)
US 2002-419009P 20021016 (60)
DT Utility
FS APPLICATION
LREP SUTHERLAND ASBILL & BRENNAN LLP, 999 PEACHTREE STREET, N.E., ATLANTA, GA, 30309, US
CLMN Number of Claims: 22
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1176
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides a composition, and a method of use thereof for treating connective tissue damage in man and in animals, which comprises a therapeutically effective amount of chondroitin sulfate, N-acetyl D-glucosamine, and hyaluronan (hyaluronic

acid). Particularly, the present invention provides a composition, and a method of use thereof, for treating connective tissue damage including, but not limited to, arthritic disease, osteoarthritis, rheumatoid arthritis, osterochondrosis dessicans, cartilage damage, joint injury, joint inflammation, joint synovitis, degenerative joint disease (DJD), post surgical DJD, traumatic injury, fracture, tendon damage, ligament damage, skeletal damage, musculoskeletal damage, fiber damage, adipose tissue damage, blood cell damage, and plasma damage. Compositions for delivery of the present invention include those for parenteral, oral, and transmucosal delivery and for direct surgical placement onto the affected tissues.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 11 OF 73 USPATFULL on STN
AN 2008:4085 USPATFULL
TI Composition and Method for Treating Rheumatoid Arthritis
IN Marcum, Frank D., Versailles, KY, UNITED STATES
Seanor, John William, Lexington, KY, UNITED STATES
PI US 20080003258 A1 20080103
AI US 2007-766525 A1 20070621 (11)
RLI Continuation-in-part of Ser. No. US 2005-105163, filed on 13 Apr 2005, PENDING Continuation-in-part of Ser. No. US 2004-15137, filed on 17 Dec 2004, PENDING Continuation-in-part of Ser. No. US 2003-686918, filed on 16 Oct 2003, GRANTED, Pat. No. US 6979679
PRAI US 2002-419009P 20021016 (60)
US 2003-487681P 20030716 (60)
DT Utility
FS APPLICATION
LREP SUTHERLAND ASBILL & BRENNAN LLP, 999 PEACHTREE STREET, N.E., ATLANTA, GA, 30309, US
CLMN Number of Claims: 52
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1250
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides a composition, and a method of use thereof, for treating connective tissue damage in man and in animals, which comprises a therapeutically effective amount of chondroitin sulfate, N-acetyl D-glucosamine, and hyaluronan (hyaluronic acid). Particularly, the present invention provides a composition, and a method of use thereof, for treating connective tissue damage including, but not limited to, arthritic disease, osteoarthritis, rheumatoid arthritis, osterochondrosis dessicans, cartilage damage, joint injury, joint inflammation, joint synovitis, degenerative joint disease (DJD), post surgical DJD, traumatic injury, fracture, tendon damage, ligament damage, skeletal damage, musculoskeletal damage, fiber damage, adipose tissue damage, blood cell damage, and plasma damage. Compositions for delivery of the present invention include those for parenteral, oral, and transmucosal delivery and for direct surgical placement onto the affected tissues.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 12 OF 73 USPATFULL on STN
AN 2008:4084 USPATFULL
TI Composition and Method for Treating Connective Tissue Damage
IN Marcum, Frank D., Lexington, KY, UNITED STATES
Seanor, John William, Lexington, KY, UNITED STATES
Northrop, Foster Harold, Crestwood, KY, UNITED STATES
PI US 20080003257 A1 20080103
AI US 2007-766510 A1 20070621 (11)

RLI Continuation-in-part of Ser. No. US 2005-105163, filed on 13 Apr 2005, PENDING Continuation-in-part of Ser. No. US 2004-15137, filed on 17 Dec 2004, PENDING Continuation-in-part of Ser. No. US 2003-686918, filed on 16 Oct 2003, GRANTED, Pat. No. US 6979679
PRAI US 2002-419009P 20021016 (60)
US 2003-487681P 20030716 (60)
DT Utility
FS APPLICATION
LREP SUTHERLAND ASBILL & BRENNAN LLP, 999 PEACHTREE STREET, N.E., ATLANTA, GA, 30309, US
CLMN Number of Claims: 61
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1296
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides a composition, and a method of use thereof for treating connective tissue damage in man and in animals, which comprises a therapeutically effective amount of chondroitin sulfate, N-acetyl D-glucosamine, and hyaluronan (hyaluronic acid). Particularly, the present invention provides a composition, and a method of use thereof, for treating connective tissue damage including, but not limited to, arthritic disease, osteoarthritis, rheumatoid arthritis, osterochondrosis dessicans, cartilage damage, joint injury, joint inflammation, joint synovitis, degenerative joint disease (DJD), post surgical DJD, traumatic injury, fracture, tendon damage, ligament damage, skeletal damage, musculoskeletal damage, fiber damage, adipose tissue damage, blood cell damage, and plasma damage. Compositions for delivery of the present invention include those for parenteral, oral, and transmucosal delivery and for direct surgical placement onto the affected tissues.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 13 OF 73 USPATFULL on STN
AN 2007:309274 USPATFULL
TI Combinations of Hyaluronic Acid and Polyunsaturated Fatty Acids
IN Chandler, Anthony Michael, Surrey, UNITED KINGDOM
PA Bionovate Limited, Cambridgeshire, UNITED KINGDOM, CB7 4EX (non-U.S. corporation)
PI US 20070270376 A1 20071122
AI US 2005-569207 A1 20050517 (11)
WO 2005-GB1890 20050517
20070420 PCT 371 date
PRAI GB 2004-11165 20040519
DT Utility
FS APPLICATION
LREP CONLEY ROSE, P.C., David A. Rose, P. O. BOX 3267, HOUSTON, TX, 77253-3267, US
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 4 Drawing Page(s)
LN.CNT 737
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A pharmaceutical or veterinary composition comprises a hyaluronic acid or a salt thereof or an ester of hyaluronic acid with an alcohol of the aliphatic, heterocyclic or cycloaliphatic series, or a sulphated form of hyaluronic acid, together with at least one eicosanoid or tetraenoic polyunsaturated fatty acid or an ester or a salt thereof, preferably in the form of an extract of fatty acids from the New Zealand Green Lipped Mussel Perna canaliculus. The compositions are active against inflammatory conditions including osteoarthritis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 14 OF 73 USPATFULL on STN
AN 2007:302262 USPATFULL
TI Immunotherapy of autoimmune disorders
IN Dunussi-Joannopoulos, Kyriaki, Belmont, MA, UNITED STATES
Iyer, Anand P., Randolph, NJ, UNITED STATES
PI US 20070264257 A1 20071115
AI US 2005-246541 A1 20051011 (11)
PRAI US 2004-616647P 20041008 (60)
US 2005-686001P 20050601 (60)
DT Utility
FS APPLICATION
LREP HUNTON & WILLIAMS LLP, INTELLECTUAL PROPERTY DEPARTMENT, 1900 K STREET, N.W., SUITE 1200, WASHINGTON, DC, 20006-1109, US
CLMN Number of Claims: 90
ECL Exemplary Claim: 1
DRWN 8 Drawing Page(s)
LN.CNT 4585
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions and methods for treating autoimmune diseases are described. In particular, the use of B cell depleting agents and cytotoxic drug/B cell depleting agent conjugates with a drug loading significantly higher than in previously reported procedures and with decreased aggregation and low conjugate fraction (LCF) in treating autoimmune diseases is described. Combination therapies and compositions for treating autoimmune diseases, including the B cell depleting agents, conjugates and/or anti-cytokine agents, are also described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 15 OF 73 USPATFULL on STN
AN 2007:297066 USPATFULL
TI Novel Piperidine Derivates as Modulators of Chemokine Receptor Ccr5.
IN Tucker, Howard, Macclesfield, UNITED KINGDOM
PI US 20070259914 A1 20071108
AI US 2005-628724 A1 20050620 (11)
WO 2005-SE952 20050620
20061207 PCT 371 date
PRAI SE 2004-1657 20040624
DT Utility
FS APPLICATION
LREP MORGAN LEWIS & BOCKIUS LLP, 1111 PENNSYLVANIA AVENUE NW, WASHINGTON, DC, 20004, US
CLMN Number of Claims: 15
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1560
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds of formula (I) compositions comprising them, processes for preparing them and their use in medical therapy (for example modulating CCR5 receptor activity in a warm blooded animal). ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 16 OF 73 USPATFULL on STN
AN 2007:285001 USPATFULL
TI Compositions and methods for viscosupplementation
IN Jay, Gregory D., Norfolk, MA, UNITED STATES
PA Mucosal Therapeutics, LLC, Wellesley, MS, UNITED STATES (U.S. corporation)
PI US 20070249557 A1 20071025

AI US 2007-784049 A1 20070405 (11)
RLI Continuation-in-part of Ser. No. US 2004-658233, PENDING A 371 of International Ser. No. WO 2005-US26004, filed on 22 Jul 2005
PRAI US 2004-590766P 20040723 (60)
DT Utility
FS APPLICATION
LREP CLARK & ELBING LLP, 101 FEDERAL STREET, BOSTON, MA, 02110, US
CLMN Number of Claims: 27
ECL Exemplary Claim: 1
DRWN 10 Drawing Page(s)
LN.CNT 1575
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides viscosupplementation compositions that include hyaluronic acid, or a polymer thereof and a tribonectin, or an analog, derivative, or fragment thereof. Such compositions are useful for the lubrication and chondroprotection of mammalian joints.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 17 OF 73 USPATFULL on STN
AN 2007:284975 USPATFULL
TI Bcma Polypeptides and Uses Thereof
IN Kelley, Robert F., San Bruno, CA, UNITED STATES
Patel, Darshana Ramesh, Burlingame, CA, UNITED STATES
PA Genentech, Inc., South San Francisco, CA, UNITED STATES, 94080-4990 (U.S. corporation)
PI US 20070249530 A1 20071025
AI US 2004-587370 A1 20040804 (10)
WO 2004-US25247 20040804
20070529 PCT 371 date
PRAI US 2004-540271P 20040129 (60)
DT Utility
FS APPLICATION
LREP MERCHANT & GOULD PC, P.O. BOX 2903, MINNEAPOLIS, MN, 55402-0903, US
CLMN Number of Claims: 50
ECL Exemplary Claim: 1
DRWN 8 Drawing Page(s)
LN.CNT 4362
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to polypeptides that inhibit APRIL and/or BAFF binding to BCMA, nucleic acid molecules encoding the polypeptides, and compositions comprising the polypeptides. The present invention also relates to methods for treating an immune-related disease or cancer using the polypeptides and compositions of the invention. The present invention also relates to methods for identifying inhibitors of APRIL/BAFF binding to BCMA and APRIL/BAFF signaling.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 18 OF 73 USPATFULL on STN
AN 2007:250489 USPATFULL
TI Class of bioactive glycoprotein
IN Yamskova, Viktoria Petrovna, Moscow, RUSSIAN FEDERATION
Yamskov, Igor Alexandrovich, Moscow, RUSSIAN FEDERATION
Rykov, Alexei Vasilievich, Moskovskay obl., RUSSIAN FEDERATION
PA Zacrytoe aktsionernoe obschestvo proizvodstvennoe predpriyatie "ENDO-FARM-A" (non-U.S. corporation)
PI US 20070219126 A1 20070920
AI US 2007-711141 A1 20070227 (11)
RLI Continuation of Ser. No. US 2002-70732, filed on 4 Apr 2002, ABANDONED A 371 of International Ser. No. WO 2000-RU295, filed on 13 Jul 2000
DT Utility

FS APPLICATION
LREP JACOBSON HOLMAN PLLC, 400 SEVENTH STREET N.W., SUITE 600, WASHINGTON, DC, 20004, US
CLMN Number of Claims: 6
ECL Exemplary Claim: 1
DRWN 16 Drawing Page(s)
LN.CNT 1236
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to a bioactive chemical composition, more specifically to proteins and can be used in medicine, veterinary and cell biology. The invented glycoproteins are extracted with the help of isoelectric focusing from intercellular space of tissues taken from different organs, blood serum and bile of the vertebrates (human beings and animals). Said glycoproteins have high biological activity in ultra low doses at concentration ranging from 10.sup.-12 to 10.sup.-29 mol/liter and lower.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 19 OF 73 USPATFULL on STN
AN 2007:243881 USPATFULL
TI COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY CONDITIONS UTILIZING PROTEIN OR POLYSACCHARIDE CONTAINING ANTI-MICROTUBULE AGENTS
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
Toleikis, Philip M., Vancouver, CANADA
PA ANGIOTECH INTERNATIONAL AG, Zug, SWITZERLAND, 6304 (non-U.S. corporation)
PI US 20070213393 A1 20070913
AI US 2007-687528 A1 20070316 (11)
RLI Continuation of Ser. No. US 2002-289150, filed on 6 Nov 2002, PENDING Continuation-in-part of Ser. No. US 2002-137736, filed on 1 May 2002, PENDING
PRAI US 2001-288017P 20010501 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENUE, SUITE 5400, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 26
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3012
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed herein are compositions and methods for treating a variety of inflammatory conditions (e.g., inflammatory arthritis, adhesions, tumor excision sites, and fibroproliferative diseases of the eye). For example, there is provided a composition comprising a protein or polysaccharide containing dispersed (e.g., in micelle or liposome form) anti-microtubule agent, which may be formulated for administration to a patient in need thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 20 OF 73 USPATFULL on STN
AN 2007:231932 USPATFULL
TI Useful indole compounds
IN Bartolini, Wilmin, Amesbury, MA, UNITED STATES
Cali, Brian M., Arlington, MA, UNITED STATES
Chen, Barbara, Northbrook, IL, UNITED STATES
Chien, Yueh-Tyng, Newton, MA, UNITED STATES
Currie, Mark G., Sterling, MA, UNITED STATES

Milne, G. Todd, Brookline, MA, UNITED STATES
Pearson, James Philip, Cambridge, MA, UNITED STATES
Talley, John Jeffrey, Somerville, MA, UNITED STATES
Yang, Jing Jing, Boxborough, MA, UNITED STATES
Zimmerman, Craig, Topsfield, MA, UNITED STATES
Monreal, Alex W., Boston, MA, UNITED STATES
PI US 20070203209 A1 20070830
AI US 2006-507099 A1 20060818 (11)
PRAI US 2005-709958P 20050818 (60)
US 2005-751443P 20051216 (60)
DT Utility
FS APPLICATION
LREP FISH & RICHARDSON PC, P.O. BOX 1022, MINNEAPOLIS, MN, 55440-1022, US
CLMN Number of Claims: 64
ECL Exemplary Claim: 1
DRWN 75 Drawing Page(s)
LN.CNT 9139
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Indoles having various activities, including indoles that are CRTH2 are described. The compounds are useful for treating asthma, neuropathic pain, allegic rhinitis and other disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 21 OF 73 USPATFULL on STN
AN 2007:225438 USPATFULL
TI Anti-vascular and anti-proliferation methods, therapies, and combinations employing specific tyrosine kinase inhibitors
IN Nesbit, Mark, Vincennes, FRANCE
Spada, Alfred P., Lansdale, PA, UNITED STATES
He, Wei, Audubon, PA, UNITED STATES
Myers, Michael R., Fishers, IN, UNITED STATES
PI US 20070197538 A1 20070823
AI US 2006-519935 A1 20060913 (11)
RLI Continuation of Ser. No. WO 2004-EP12185, filed on 7 Oct 2004, UNKNOWN
DT Utility
FS APPLICATION
LREP WILEY REIN LLP, 1776 K. STREET N.W., WASHINGTON, DC, 20006, US
CLMN Number of Claims: 50
ECL Exemplary Claim: 1
DRWN 6 Drawing Page(s)
LN.CNT 5603
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention is directed to potent inhibitors of protein tyrosine kinase alone or in synergistic combination with antiangiogenic or chemotherapeutic agents for the abrogation of mature vasculature within chemotherapeutic refractory tumors, pharmaceutical compositions comprising these compounds, and to the use of these compounds for treating a patient suffering from or subject to disorders/conditions involving cell proliferation, and particularly treatment of brain cancer, ovarian cancer, pancreatic cancer prostate cancer, and human leukemias, such as CML, AML or ALL.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 22 OF 73 USPATFULL on STN
AN 2007:225371 USPATFULL
TI Treatment of degenerative cartilage conditions in a mammal with Glycosidasc Inhibitors
IN Ichikawa, Yoshitaka, San DIego, CA, UNITED STATES
PA Optimer Pharmaceuticals, Inc., San Diego, CA, UNITED STATES, 92121 (U.S. corporation)

The Scripps Research Institute, LaJolla, CA, UNITED STATES, 92037 (U.S. corporation)
PI US 20070197471 A1 20070823
AI US 2005-586578 A1 20050120 (10)
WO 2005-US2017 20050120
20060925 PCT 371 date
PRAI US 2004-531168P 20040120 (60)
DT Utility
FS APPLICATION
LREP CATALYST LAW GROUP, APC, 9710 SCRANTON ROAD, SUITE S-170, SAN DIEGO, CA, 92121, US
CLMN Number of Claims: 42
ECL Exemplary Claim: 1
DRWN 3 Drawing Page(s)
LN.CNT 871
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to treating, preventing, and lessening the severity of conditions selected from the group consisting of osteoarthritis, rheumatoid arthritis, synovitis, subchondral bone edema, and cartilage degradation with administration of glycosidase inhibitors.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 23 OF 73 USPATFULL on STN
AN 2007:225334 USPATFULL
TI Theurapeutic or prophyiactic agent for arthritis
IN Nakao, Kazuwa, Kyoto, JAPAN
Kitamura, Hidetomo, Shizuoka, JAPAN
PI US 20070197434 A1 20070823
AI US 2005-594920 A1 20050331 (10)
WO 2005-JP6831 20050331
20060929 PCT 371 date
PRAI JP 2004-107924 20040331
DT Utility
FS APPLICATION
LREP BIRCH STEWART KOLASCH & BIRCH, PO BOX 747, FALLS CHURCH, VA, 22040-0747, US
CLMN Number of Claims: 51
ECL Exemplary Claim: 1
DRWN 13 Drawing Page(s)
LN.CNT 1794
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention provides a new therapeutic or prophylactic agent for arthritis such as osteoarthritis. Specifically, it provides a therapeutic or prophylactic agent for arthritis such as osteoarthritis, or an agent for promoting the growth of articular chondrocyte, comprising a guanyl cyclase B (GC-B) activator as an active ingredient; or a method for inhibiting arthritis or for promoting the growth of articular chondrocyte by activating GC-B; or a method for screening an agent for promoting the growth of articular chondrocyte or an agent capable of treating arthritis using the GC-B activity as an indication.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 24 OF 73 USPATFULL on STN
AN 2007:177911 USPATFULL
TI Aryl or Heteroaryl Fused Imidazole Compounds as Anti-Inflammatory and Analgesic Agents
IN Nakao, Kazunari, Chita-gun, JAPAN
Okumura, Yoshiyuki, Chita-gun, JAPAN
Matsumizu, Miyako, Chita-gun, JAPAN

Ueno, Naomi, Chita-gun, JAPAN
Hashizume, Yoshinobu, Chita-gun, JAPAN
Kato, Tomoki, Chita-gun, JAPAN
Kawai, Akiyoshi, Chita-gun, JAPAN
Miyake, Yoriko, Chita-gun, JAPAN
Nukui, Seiji, Chita-gun, JAPAN
Shinjyo, Katsuhiro, Chita-gun, JAPAN
Taniguchi, Kana, Chita-gun, JAPAN
PA Pfizer Inc. (non-U.S. corporation)
PI US 20070155732 A1 20070705
AI US 2006-556523 A1 20061103 (11)
RLI Division of Ser. No. US 2004-771696, filed on 4 Feb 2004, GRANTED, Pat. No. US 7141580 Division of Ser. No. US 2001-977621, filed on 15 Oct 2001, GRANTED, Pat. No. US 6710054
PRAI US 2000-241825P 20001019 (60)
DT Utility
FS APPLICATION
LREP WARNER-LAMBERT COMPANY, 2800 PLYMOUTH RD, ANN ARBOR, MI, 48105, US
CLMN Number of Claims: 16
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 15261
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention provides a compound of the formula (I): ##STR1## or the pharmaceutically acceptable salts thereof, wherein Y.sup.1, Y.sup.2, Y.sup.3 and Y.sup.4 are independently selected from N, CH, etc.; R.sup.1 is H, C.sub.1-8 alkyl, etc.; Q.sup.1 is a 5-12 membered monocyclic or bicyclic aromatic ring optionally containing up to 4 heteroatoms selected from O, N and S, etc.; A is a 5-6 membered monocyclic aromatic ring optionally containing up to 3 heteroatoms selected from O, N and S, etc.; B is C.sub.1-6 alkylene optionally substituted with an oxo group, etc.; W is NH, O, etc.; R.sup.2 is H, C.sub.1-4 alkyl, etc.; Z is a 5-12 membered monocyclic or bicyclic aromatic ring optionally containing up to 3 heteroatoms selected from O, N and S, etc.; L is halo, C.sub.1-4 alkyl, etc.; m is 0, 1 or 2; R.sup.3 and R.sup.4 are independently selected from H and C.sub.1-4 alkyl ; R.sup.5 is H, C.sub.1-4 alkyl, etc.; Q.sup.2 is a 5-12 membered monocyclic or bicyclic aromatic ring or tricyclic ring optionally containing up to 3 heteroatoms selected from O, N and S, etc. These compounds are useful for the treatment of medical conditions mediated by prostaglamadin such as pain, fever or inflammation, etc. This invention also provides a pharmaceutical composition comprising the above compound.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 25 OF 73 USPATFULL on STN
AN 2007:177845 USPATFULL
TI Canine and equine collagen joint health supplement
IN Alkayali, Ahmad, Lake Forest, CA, UNITED STATES
Quadri, Sarah, Orange, CA, UNITED STATES
PI US 20070155666 A1 20070705
AI US 2007-706110 A1 20070214 (11)
RLI Continuation-in-part of Ser. No. US 2006-517233, filed on 7 Sep 2006, PENDING Continuation-in-part of Ser. No. US 2004-909204, filed on 30 Jul 2004, PENDING Continuation-in-part of Ser. No. US 2001-768141, filed on 24 Jan 2001, GRANTED, Pat. No. US 6838440
PRAI US 2006-782130P 20060314 (60)
DT Utility
FS APPLICATION
LREP Law Office of Terry L. Miller, 24832 Via San Fernando, Mission Viejo, CA, 92692, US
CLMN Number of Claims: 31

ECL Exemplary Claim: 1
DRWN 4 Drawing Page(s)
LN.CNT 681
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A food supplement for administration to mammals, and particularly for dogs and horses, has been shown to have a beneficial effect against degenerative joint conditions. The food supplement includes collagen kolla2®.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 26 OF 73 USPATFULL on STN
AN 2007:162770 USPATFULL
TI Treatment of a condition in a mammal with administration of aminosugar and uses thereof
IN SHUE, Youe-Kong, Carlsbad, CA, UNITED STATES
PI US 20070142326 A1 20070621
AI US 2004-574054 A1 20040930 (10)
WO 2004-US32048 20040930
20060607 PCT 371 date
DT Utility
FS APPLICATION
LREP CATALYST LAW GROUP, APC, 9710 SCRANTON ROAD, SUITE S-170, SAN DIEGO, CA, 92121, US
CLMN Number of Claims: 33
ECL Exemplary Claim: 1
DRWN 5 Drawing Page(s)
LN.CNT 1110
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to treating joint related conditions in mammals by administering an aminosugar, and wherein said treatment specifically prevents, lessens or reverses pathologies associated with the joint condition, said pathologies being selected from the group consisting of synovitis, subchondral bone edema, and cartilage degradation.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 27 OF 73 USPATFULL on STN
AN 2007:95149 USPATFULL
TI Treatment of a condition in a mammal with administration of Compounds and Methods of Use
IN Ichikawa, Yoshitaka, San Diego, CA, UNITED STATES
PA Optimer Pharmaceuticals Inc., San Diego, CA, UNITED STATES (U.S. corporation)
The Scripps Research Institute, La Jolla, CA, UNITED STATES (U.S. corporation)
PI US 20070082851 A1 20070412
AI US 2004-580512 A1 20041123 (10)
WO 2004-US39680 20041123
20060523 PCT 371 date
PRAI US 2003-524698P 20031124 (60)
DT Utility
FS APPLICATION
LREP CATALYST LAW GROUP, APC, 9710 SCRANTON ROAD, SUITE S-170, SAN DIEGO, CA, 92121, US
CLMN Number of Claims: 92
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2022
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to methods of treating, preventing, and lessening

the severity of conditions or diseases selected from the group consisting of osteoarthritis (OA), rheumatoid arthritis, synovitis, subchondral bone edema, and cartilage degradation ("OA and related disorders") with administration of an aminosugar derivative and pharmaceutically acceptable salts thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 28 OF 73 USPATFULL on STN
AN 2007:55431 USPATFULL
TI Method for treating non-inflammatory osteoarthritic pain
IN Beyreuther, Bettina, Dusseldorf, GERMANY, FEDERAL REPUBLIC OF
Stohr, Thomas, Monheim, GERMANY, FEDERAL REPUBLIC OF
PA SRZ Properties, Inc., Wilmington, DE, UNITED STATES (U.S. corporation)
PI US 20070048372 A1 20070301
AI US 2006-506578 A1 20060818 (11)
PRAI EP 2005-17977 20050818
US 2006-811840P 20060608 (60)
DT Utility
FS APPLICATION
LREP HARNESS, DICKEY, & PIERCE, P.L.C, 7700 BONHOMME, STE 400, ST. LOUIS, MO, 63105, US
CLMN Number of Claims: 23
ECL Exemplary Claim: 1
DRWN 8 Drawing Page(s)
LN.CNT 1877
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method for treating non-inflammatory osteoarthritic pain in a subject comprises administering to the subject a compound as defined herein, illustratively lacosamide, or a pharmaceutically acceptable salt thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 29 OF 73 USPATFULL on STN
AN 2007:49294 USPATFULL
TI Therapeutic combination for painful medical conditions
IN Beyreuther, Bettina, Dusseldorf, GERMANY, FEDERAL REPUBLIC OF
Stohr, Thomas, Monheim, GERMANY, FEDERAL REPUBLIC OF
PI US 20070043120 A1 20070222
AI US 2006-506524 A1 20060818 (11)
PRAI EP 2005-17977 20050818
US 2006-811859P 20060608 (60)
DT Utility
FS APPLICATION
LREP HARNESS, DICKEY, & PIERCE, P.L.C, 7700 BONHOMME, STE 400, ST. LOUIS, MO, 63105, US
CLMN Number of Claims: 51
ECL Exemplary Claim: 1
DRWN 8 Drawing Page(s)
LN.CNT 2191
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A therapeutic combination comprises a first agent comprising a compound as defined herein, illustratively lacosamide, or a pharmaceutically acceptable salt thereof, and a second agent effective in combination therewith to (a) provide enhanced treatment of pain associated with or caused by a medical condition, by comparison with the first agent alone; and/or (b) treat another symptom or an underlying cause of the medical condition. The combination can be provided in a single dosage form or separate dosage forms and is illustratively useful for treatment of an arthritic condition and/or pain related thereto.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 30 OF 73 USPATFULL on STN
AN 2007:23213 USPATFULL
TI Methods and compositions for treatment of inflammatory disease
IN Levin, Bruce, Philadelphia, PA, UNITED STATES
PI US 20070020254 A1 20070125
AI US 2006-526946 A1 20060925 (11)
RLI Division of Ser. No. US 2004-756695, filed on 12 Jan 2004, GRANTED, Pat. No. US 7112578 Continuation of Ser. No. US 2000-724645, filed on 28 Nov 2000, GRANTED, Pat. No. US 6677321
PRAI US 1999-169845P 19991209 (60)
DT Utility
FS APPLICATION
LREP KENYON & KENYON LLP, ONE BROADWAY, NEW YORK, NY, 10004, US
CLMN Number of Claims: 25
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 629
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions useful for treating inflammatory diseases including arthritis are disclosed which comprise cetyl myristoleate compounds or related compounds and at least one compound useful for treatment of inflammatory disease, such as tetracycline compounds, Cox-2 inhibitors, non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, local anaesthetics, chelating agents, matrix metalloprotease inhibitors, inhibitors of inflammatory cytokines, glucosamine, chondroitin sulfate and collagen hydrolysate. Also disclosed are pharmaceutical compositions and methods of treatment for inflammatory disease and local inflammation and dermal irritation. Also disclosed are compositions including tetracycline and at least one compound useful for treatment of inflammatory disease.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 31 OF 73 USPATFULL on STN
AN 2006:308830 USPATFULL
TI Treatment of rheumatoid arthritis
IN Joensuu, Heikki, Espoo, FINLAND
PI US 20060264443 A1 20061123
AI US 2003-502534 A1 20030127 (10)
WO 2003-EP802 20030127
20050105 PCT 371 date
PRAI GB 2002-1882 20020128
DT Utility
FS APPLICATION
LREP NOVARTIS, CORPORATE INTELLECTUAL PROPERTY, ONE HEALTH PLAZA 104/3, EAST HANOVER, NJ, 07936-1080, US
CLMN Number of Claims: 21
ECL Exemplary Claim: 1-19
DRWN No Drawings
LN.CNT 570
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide of the formula I ##STR1## or a pharmaceutically acceptable salt thereof can be used in the treatment of rheumatoid arthritis. The invention also relates to a combination of the compound of the formula I or a pharmaceutically acceptable salt thereof with one or more disease modifying arthritis rheumatoid drugs (DMARDs).

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 32 OF 73 USPATFULL on STN
AN 2006:247163 USPATFULL
TI Compositions and methods for systemic inhibition of cartilage degradation
IN Demopulos, Gregory A., Mercer Island, WA, UNITED STATES
Palmer, Pamela Pierce, San Francisco, CA, UNITED STATES
Herz, Jeffrey M., Mill Creek, WA, UNITED STATES
PA Omeros Corporation (U.S. corporation)
PI US 20060210552 A1 20060921
AI US 2006-436941 A1 20060518 (11)
RLI Continuation of Ser. No. US 2003-356649, filed on 31 Jan 2003, GRANTED, Pat. No. US 7067144 Continuation-in-part of Ser. No. US 2002-31546, filed on 18 Jan 2002, PENDING A 371 of International Ser. No. WO 2000-US19864, filed on 21 Jul 2000 Continuation-in-part of Ser. No. US 2001-839633, filed on 20 Apr 2001, PENDING Continuation-in-part of Ser. No. WO 1999-US26330, filed on 5 Nov 1999, PENDING Continuation-in-part of Ser. No. WO 1999-US24625, filed on 20 Oct 1999, PENDING
PRAI US 2002-353552P 20020201 (60)
US 1999-144904P 19990721 (60)
US 1998-107256P 19981105 (60)
US 1998-105026P 19981020 (60)
DT Utility
FS APPLICATION
LREP Marcia S. Kelbon, Esq., OMEROS CORPORATION, Suite 2600, 1420 Fifth Avenue, Seattle, WA, 98101, US
CLMN Number of Claims: 22
ECL Exemplary Claim: 1-66
DRWN 9 Drawing Page(s)
LN.CNT 5693
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods and compositions for inhibiting articular cartilage degradation. The compositions preferably include multiple chondroprotective agents, including at least one agent that promotes cartilage anabolic activity and at least one agent that inhibits cartilage catabolism. The compositions may also include one or more pain and inflammation inhibitory agents. The compositions may be administered systemically, such as to treat patients at risk of cartilage degradation at multiple joints, and suitably may be formulated in a carrier or delivery vehicle that is targeted to the joints. Alternatively the compositions may be injected or infused directly into the joint.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 33 OF 73 USPATFULL on STN
AN 2006:159935 USPATFULL
TI Composition and method for treatment and prevention of traumatic synovitis and damage to articular cartilage
IN Marcum, Frank, Lexington, KY, UNITED STATES
PI US 20060135470 A1 20060622
AI US 2004-15137 A1 20041217 (11)
DT Utility
FS APPLICATION
LREP STOCKWELL & ASSOCIATES, PSC, 861 CORPORATE DRIVE, SUITE 201, LEXINGTON, KY, 40503, US
CLMN Number of Claims: 36
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 841
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides compositions useful for the treatment and/or prevention of damage to diarthrodial (synovial) joints and, in particular, traumatic synovitis, inflammation of the synovial

membrane, and damage to the articular cartilage of the joint. Specifically, provided are compositions specially formulated for intra-articular and/or parenteral use in the treatment and/or prevention of traumaticsynovitis and/or damage to articular cartilage. Compositions adapted specifically for post surgical joint lavage or treatment and/or prevention of inflammatory arthritis, osteoarthritis (OA) and/or degenerative joint disease (DJD) are also provided. Compositions adapted for intra-articular and/or systemic administration comprised of therapeutic amounts of: chondroitin sulfate and hyaluronan (hyaluronic acid) are provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 34 OF 73 USPATFULL on STN
AN 2006:159895 USPATFULL
TI BLy antagonists and uses thereof
IN Chan, Andrew Chen-Yuen, Menlo Park, CA, UNITED STATES
Gordon, Nathaniel C., Berkeley, CA, UNITED STATES
Kelley, Robert F., San Bruno, CA, UNITED STATES
Koehler, Michael F.T., Burlingame, CA, UNITED STATES
Starovasnik, Melissa A., San Francisco, CA, UNITED STATES
PA GENENTECH, INC., SOUTH SAN FRANCISCO, CA, UNITED STATES (U.S. corporation)
PI US 20060135430 A1 20060622
AI US 2005-291698 A1 20051130 (11)
RLI Continuation of Ser. No. WO 2004-US17682, filed on 4 Jun 2004, PENDING
PRAI US 2003-476414P 20030605 (60)
US 2003-476531P 20030606 (60)
US 2003-476481P 20030605 (60)
DT Utility
FS APPLICATION
LREP MERCHANT & GOULD PC, P.O. BOX 2903, MINNEAPOLIS, MN, 55402-0903, US
CLMN Number of Claims: 91
ECL Exemplary Claim: 1
DRWN 24 Drawing Page(s)
LN.CNT 5748
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to polypeptides that block BLyS signaling, nucleic acid molecules encoding the polypeptides, and compositions comprising the polypeptides. The present invention also relates to methods for treating an immune-related disease or cancer using the polypeptides and compositions of the invention. The present invention also relates to methods for identifying inhibitors of BLyS signaling.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 35 OF 73 USPATFULL on STN
AN 2005:209538 USPATFULL
TI Chondroprotective/restorative compositions and methods of use thereof
IN Pierce, Scott W., Lexington, KY, UNITED STATES
PI US 20050182022 A1 20050818
AI US 2005-95632 A1 20050401 (11)
RLI Continuation of Ser. No. US 2001-967977, filed on 2 Oct 2001, PENDING
PRAI US 2000-237838P 20001003 (60)
DT Utility
FS APPLICATION
LREP Isaac A. Angres, Suite 301, 2001 Jefferson Davis Highway, Arlington, VA, 22202, US
CLMN Number of Claims: 19
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1235

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The instant invention provides a method of treating or preventing osteoarthritis, joint effusion, joint inflammation and pain, synovitis, lameness, post operative arthroscopic surgery, deterioration of proper joint function including joint mobility, the reduction or inhibition of metabolic activity of chondrocytes, the activity of enzymes that degrade cartilage, the reduction or inhibition of the production of Hyaluronic acid, said method comprising orally administering to a mammalian species a therapeutically effective amount of Hyaluronic Acid or pharmaceutically acceptable salts thereof. Additionally, compositions containing hyaluronic acid; chondroitin sulfate, and glucosamine sulfate in a paste formulation are also disclosed which can be administered on their own or can be used as a feed additive.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 36 OF 73 USPATFULL on STN
AN 2005:23953 USPATFULL
TI Nutraceuticals for the treatment, protection and restoration of connective tissues
IN Shen, Bojang, Berala, AUSTRALIA
Ghosh, Peter, Fairlight, AUSTRALIA
PI US 20050020500 A1 20050127
US 7371820 B2 20080513
AI US 2004-896546 A1 20040722 (10)
RLI Continuation-in-part of Ser. No. WO 2003-AU61, filed on 23 Jan 2003, UNKNOWN
PRAI AU 2002-112 20020123
AU 2002-1054 20020312
DT Utility
FS APPLICATION
LREP FROMMER LAWRENCE & HAUG, 745 FIFTH AVENUE- 10TH FL., NEW YORK, NY, 10151
CLMN Number of Claims: 34
ECL Exemplary Claim: 1
DRWN 35 Drawing Page(s)
LN.CNT 2082
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to a method for isolating from connective tissue a variety of glycosminoglycan (GAG)-polypeptide complexes and polypeptides which are substantially free of contaminating DNA and other molecules such as viruses which may be associated with the DNA in the cell. The invention also relates to uses of GAG-peptide complexes and polypeptides substantially free of DNA either directly, or after further processing, for the treatment, protection and restoration of connective tissues in inflammatory and degenerative disorders such as rheumatoid arthritis and osteoarthritis in any of their multiple forms or other degenerative conditions in mammals.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 37 OF 73 USPATFULL on STN
AN 2004:233985 USPATFULL
TI Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents
IN Nakao, Kazunari, Aichi-ken, JAPAN
Okumura, Yoshiyuki, Aichi-ken, JAPAN
Matsumizu, Miyako, Aichi-ken, JAPAN
Ueno, Naomi, Aichi-ken, JAPAN
Hashizume, Yoshinobu, Aichi-ken, JAPAN
Kato, Tomoki, Aichi-ken, JAPAN
Kawai, Akiyoshi, Aichi-ken, JAPAN

Miyake, Yoriko, Aichi-ken, JAPAN
Nukui, Seiji, Aichi-ken, JAPAN
Shinjyo, Katsuhiro, Aichi-ken, JAPAN
Taniguchi, Kana, Aichi-ken, JAPAN
PI US 20040181059 A1 20040916
US 7141580 B2 20061128
AI US 2004-771696 A1 20040204 (10)
RLI Division of Ser. No. US 2001-977621, filed on 15 Oct 2001, GRANTED, Pat. No. US 6710054
PRAI US 2000-241825P 20001019 (60)
DT Utility
FS APPLICATION
LREP WARNER-LAMBERT COMPANY, 2800 PLYMOUTH RD, ANN ARBOR, MI, 48105
CLMN Number of Claims: 16
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 15947
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention provides a compound of the formula (I): ##STR1##

or the pharmaceutically acceptable salts thereof, wherein Y.sup.1, Y.sup.2, Y.sup.3 and Y.sup.4 are independently selected from N, CH, etc.; R.sup.1 is H, C.sub.1-8 alkyl, etc.; Q.sup.1 is a 5-12 membered monocyclic or bicyclic aromatic ring optionally containing up to 4 heteroatoms selected from O, N and S, etc.; A is a 5-6 membered monocyclic aromatic ring optionally containing up to 3 heteroatoms selected from O, N and S, etc.; B is C.sub.1-6 alkylene optionally substituted with an oxo group, etc.; W is NH, O, etc.; R.sup.2 is H, C.sub.1-4 alkyl, etc.; Z is a 5-12 membered monocyclic or bicyclic aromatic ring optionally containing up to 3 heteroatoms selected from O, N and S, etc.; L is halo, C.sub.1-4 alkyl, etc.; m is 0, 1 or 2; R.sup.3 and R.sup.4 are independently selected from H and C.sub.1-4 alkyl; R.sup.5 is H, C.sub.1-4 alkyl, etc.; Q.sup.2 is a 5-12 membered monocyclic or bicyclic aromatic ring or tricyclic ring optionally containing up to 3 heteroatoms selected from O, N and S, etc. These compounds are useful for the treatment of medical conditions mediated by prostaglamndin such as pain, fever or inflammation, etc. This invention also provides a pharmaceutical composition comprising the above compound.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 38 OF 73 USPATFULL on STN
AN 2004:190672 USPATFULL
TI Methods and compositions for treatment of inflammatory disease
IN Levin, Bruce, Philadelphia, PA, UNITED STATES
PI US 20040147445 A1 20040729
US 7112578 B2 20060926
AI US 2004-756695 A1 20040112 (10)
RLI Continuation of Ser. No. US 2000-724645, filed on 28 Nov 2000, GRANTED, Pat. No. US 6677321
PRAI US 1999-169845P 19991209 (60)
DT Utility
FS APPLICATION
LREP KENYON & KENYON, ONE BROADWAY, NEW YORK, NY, 10004
CLMN Number of Claims: 62
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 770
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions useful for treating inflammatory diseases including arthritis are disclosed which comprise cetyl myristoleate compounds or

related compounds and at least one compound useful for treatment of inflammatory disease, such as tetracycline compounds, Cox-2 inhibitors, non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, local anaesthetics, chelating agents, matrix metalloprotease inhibitors, inhibitors of inflammatory cytokines, glucosamine, chondroitin sulfate and collagen hydrolysate. Also disclosed are pharmaceutical compositions and methods of treatment for inflammatory disease and local inflammation and dermal irritation. Also disclosed are compositions including tetracycline and at least one compound useful for treatment of inflammatory disease.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 39 OF 73 USPATFULL on STN
AN 2004:121064 USPATFULL
TI Composition and method for treatment and prevention of traumatic synovitis and damage to articular cartilage
IN Marcum, Frank D., Lexington, KY, UNITED STATES
PI US 20040092479 A1 20040513
US 6979679 B2 20051227
AI US 2003-686918 A1 20031016 (10)
PRAI US 2002-419009P 20021016 (60)
US 2003-487681P 20030716 (60)
DT Utility
FS APPLICATION
LREP STOCKWELL & ASSOCIATES, PSC, 861 CORPORATE DRIVE, SUITE 201, LEXINGTON, KY, 40503
CLMN Number of Claims: 36
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 844
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides compositions useful for the treatment and/or prevention of damage to diarthrodial (synovial) joints and, in particular, traumatic synovitis, inflammation of the synovial membrane, and damage to the articular cartilage of the joint. Specifically, provided are compositions specially formulated for intra-articular and/or parenteral use in the treatment and/or prevention of traumaticsynovitis and/or damage to articular cartilage. Compositions adapted specifically for post surgical joint lavage or treatment and/or prevention of inflammatory arthritis, osteoarthritis (OA) and/or degenerative joint disease (DJD) are also provided. Compositions adapted for intra-articular and/or systemic administration comprised of therapeutic amounts of: chondroitin sulfate; N-acetyl D-glucosamine; and hyaluronan (hyaluronic acid) are provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 40 OF 73 USPATFULL on STN
AN 2004:88227 USPATFULL
TI Targeted therapeutic lipid constructs
IN Brunke, Karen J., Belmont, CA, UNITED STATES
Wartchow, Charles A., San Francisco, CA, UNITED STATES
Cleland, Jeffrey L., San Carlos, CA, UNITED STATES
PI US 20040067196 A1 20040408
AI US 2003-401280 A1 20030327 (10)
RLI Continuation-in-part of Ser. No. US 2001-976254, filed on 11 Oct 2001, PENDING
PRAI US 2000-239684P 20001011 (60)
US 2002-367858P 20020327 (60)
DT Utility

FS APPLICATION
LREP SWANSON & BRATSCHUN L.L.C., 1745 SHEA CENTER DRIVE, SUITE 330, HIGHLANDS RANCH, CO, 80129
CLMN Number of Claims: 15
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 2334
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Novel therapeutic lipid constructs comprising a lipid construct, an anti-cell surface targeting agent, and a radiotherapeutic metal ion are disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 41 OF 73 USPATFULL on STN
AN 2004:9603 USPATFULL
TI Methods and compositions for treatment of inflammatory disease
IN Levin, Bruce, One Independence Place, Philadelphia, PA, United States 19106
PA Levin, Bruce, Philadelphia, PA, United States (U.S. individual)
PI US 6677321 B1 20040113
AI US 2000-724645 20001128 (9)
PRAI US 1999-169845P 19991209 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Shah, Mukund J.; Assistant Examiner: Tucker, Zachary C.
LREP Kenyon & Kenyon
CLMN Number of Claims: 25
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 668
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions useful for treating inflammatory diseases including arthritis are disclosed which comprise cetyl myristoleate compounds or related compounds and at least one compound useful for treatment of inflammatory disease, such as tetracycline compounds, Cox-2 inhibitors, non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, local anaesthetics, chelating agents, matrix metalloprotease inhibitors, inhibitors of inflammatory cytokines, glucosamine, chondroitin sulfate and collagen hydrolysate. Also disclosed are pharmaceutical compositions and methods of treatment for inflammatory disease and local inflammation and dermal irritation. Also disclosed are compositions including tetracycline and at least one compound useful for treatment of inflammatory disease.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 42 OF 73 USPATFULL on STN
AN 2003:334713 USPATFULL
TI Compositions and methods for systemic inhibition of cartilage degradation
IN Demopulos, Gregory A., Mercer Island, WA, UNITED STATES
Palmer, Pamela Pierce, San Francisco, CA, UNITED STATES
Herz, Jeffrey M., Mill Creek, WA, UNITED STATES
PA Omeros Corporation (U.S. corporation)
PI US 20030235589 A1 20031225
US 7067144 B2 20060627
AI US 2003-356649 A1 20030131 (10)
RLI Continuation-in-part of Ser. No. US 2002-31546, filed on 18 Jan 2002, PENDING A 371 of International Ser. No. WO 2000-US19864, filed on 21 Jul 2000, PENDING Continuation-in-part of Ser. No. US 2001-839633, filed on

20 Apr 2001, PENDING Continuation-in-part of Ser. No. WO 1999-US26330, filed on 5 Nov 1999, PENDING Continuation-in-part of Ser. No. WO 1999-US24625, filed on 20 Oct 1999, PENDING
PRAI US 2002-353552P 20020201 (60)
US 1999-144904P 19990721 (60)
US 1998-107256P 19981105 (60)
US 1998-105026P 19981020 (60)
DT Utility
FS APPLICATION
LREP OMEROS MEDICAL SYSTEMS, INC., 1420 FIFTH AVENUE, SUITE 2675, SEATTLE, WA, 98101
CLMN Number of Claims: 155
ECL Exemplary Claim: 1
DRWN 9 Drawing Page(s)
LN.CNT 6575
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods and compositions for inhibiting articular cartilage degradation. The compositions preferably include multiple chondroprotective agents, including at least one agent that promotes cartilage anabolic activity and at least one agent that inhibits cartilage catabolism. The compositions may also include one or more pain and inflammation inhibitory agents. The compositions may be administered systemically, such as to treat patients at risk of cartilage degradation at multiple joints, and suitably may be formulated in a carrier or delivery vehicle that is targeted to the joints. Alternatively the compositions may be injected or infused directly into the joint.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 43 OF 73 USPATFULL on STN
AN 2003:300766 USPATFULL
TI Method for treating cartilage disorders
IN Chen, Yvonne Man-Yee, San Mateo, CA, UNITED STATES
Clark, Ross G., Devonport, NEW ZEALAND
Cochran, Andrea G., San Francisco, CA, UNITED STATES
Dubaquie, Yves, Lawrenceville, NJ, UNITED STATES
Fielder, Paul J., Redwood City, CA, UNITED STATES
Filvaroff, Ellen, San Francisco, CA, UNITED STATES
Lowman, Henry B., El Granada, CA, UNITED STATES
Mortensen, Deborah L., Pacifica, CA, UNITED STATES
Robinson, Iain C.A.F., St. Albans, UNITED KINGDOM
Skelton, Nicholas J., San Mateo, CA, UNITED STATES
PA GENENTECH, INC. (U.S. corporation)
PI US 20030211992 A1 20031113
US 7423017 B2 20080909
AI US 2002-271869 A1 20021016 (10)
RLI Continuation of Ser. No. US 2001-858935, filed on 16 May 2001, PENDING Continuation-in-part of Ser. No. US 1999-337227, filed on 22 Jun 1999, GRANTED, Pat. No. US 6420518 Continuation-in-part of Ser. No. US 1998-52888, filed on 31 Mar 1998, GRANTED, Pat. No. US 6251865 Continuation-in-part of Ser. No. US 1997-825852, filed on 4 Apr 1997, GRANTED, Pat. No. US 6121416 Continuation-in-part of Ser. No. US 2000-477923, filed on 5 Jan 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-477924, filed on 5 Jan 2000, GRANTED, Pat. No. US 6403764
PRAI US 2000-248985P 20001115 (60)
US 2000-204490P 20000516 (60)
US 1999-115010P 19990106 (60)
US 1999-115010P 19990106 (60)
US 1999-170261P 19991209 (60)
DT Utility
FS APPLICATION
LREP GENENTECH, INC., 1 DNA WAY, SOUTH SAN FRANCISCO, CA, 94080

CLMN Number of Claims: 26
ECL Exemplary Claim: 1
DRWN 35 Drawing Page(s)
LN.CNT 5279
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to a method for the treatment of a cartilage disorder, including cartilage damaged by injury or degenerative cartilagenous disorders. The method involves contacting the cartilage with an IGF-1 analog with altered affinity for IGF-binding proteins (IGFBPs) or an IGFBP displacer peptide that prevents the interaction of an IGF with an IGFBP and does not bind to a human IGF receptor.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 44 OF 73 USPATFULL on STN
AN 2003:294879 USPATFULL
TI Selective inhibitors of cyclooxygenase-2
IN DeMello, Kristin Lundy, Ledyard, CT, UNITED STATES
Bronk, Brian S., Gales Ferry, CT, UNITED STATES
Crosson, Rhonda Marie, Ann Arbor, MI, UNITED STATES
PA Pfizer Inc. (U.S. corporation)
PI US 20030207897 A1 20031106
US 6846818 B2 20050125
AI US 2003-414856 A1 20030416 (10)
PRAI US 2002-374372P 20020422 (60)
DT Utility
FS APPLICATION
LREP PFIZER INC., PATENT DEPARTMENT, MS8260-1611, EASTERN POINT ROAD, GROTON, CT, 06340
CLMN Number of Claims: 26
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2055
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to cyclooxygenase-2 (COX-2) selective inhibitors of formula I: ##STR1##

pharmaceutical compositions containing them, to their medicinal use, and to their preparations. The compounds of the invention are particularly useful in the treatment or alleviation of inflammation and inflammation associated disorders, such as, for example, rheumatoid arthritis and osteoarthritis, and in the relief of pain, such as, for example, pain associated with surgery or trauma, in mammals, preferably felines and canines.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 45 OF 73 USPATFULL on STN
AN 2003:225350 USPATFULL
TI Compositions and methods for treating inflammatory conditions utilizing protein or polysaccharide containing anti-microtubule agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
Toleikis, Philip M., Vancouver, CANADA
PA Angiotech Pharmaceuticals, Inc., Vancouver, CANADA (non-U.S. corporation)
PI US 20030157161 A1 20030821
AI US 2002-289150 A1 20021106 (10)
RLI Continuation-in-part of Ser. No. US 2002-137736, filed on 1 May 2002, PENDING

PRAI US 2001-288017P 20010501 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092
CLMN Number of Claims: 125
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3305
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed herein are compositions and methods for treating a variety of inflammatory conditions (e.g., inflammatory arthritis, adhesions, tumor excision sites, and fibroproliferative diseases of the eye). For example, there is provided a composition comprising a protein or polysaccharide containing dispersed (e.g., in micelle or liposome form) anti-microtubule agent, which may be formulated for administration to a patient in need thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 46 OF 73 USPATFULL on STN
AN 2003:119619 USPATFULL
TI Targeted therapeutic lipid constructs having cell surface targets
IN Wartchow, Charles Aaron, San Carlos, CA, UNITED STATES
Pease, John S., Los Altos, CA, UNITED STATES
Shen, Zhi Min, Palo Alto, CA, UNITED STATES
PA TARGESOME, INC. (U.S. corporation)
PI US 20030082103 A1 20030501
AI US 2002-262576 A1 20021001 (10)
RLI Continuation-in-part of Ser. No. US 2001-976254, filed on 11 Oct 2001, PENDING
PRAI US 2000-239684P 20001011 (60)
US 2001-326310P 20011001 (60)
DT Utility
FS APPLICATION
LREP SWANSON & BRATSCHUN L.L.C., 1745 SHEA CENTER DRIVE, SUITE 330, HIGHLANDS RANCH, CO, 80129
CLMN Number of Claims: 32
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 2294
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Novel therapeutic lipid constructs comprising a polymerized liposome, an anti-cell surface targeting agent, and a radiotherapeutic metal ion are disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 47 OF 73 USPATFULL on STN
AN 2003:100067 USPATFULL
TI Method for treating cartilage disorders
IN Dubaquie, Yves, Princeton, NJ, UNITED STATES
Filvaroff, Ellen, San Francisco, CA, UNITED STATES
Lowman, Henry B., El Granada, CA, UNITED STATES
PA GENENTECH, INC. (U.S. corporation)
PI US 20030069177 A1 20030410
AI US 2001-858935 A1 20010516 (9)
PRAI US 2000-248985P 20001115 (60)
US 2000-204490P 20000516 (60)
DT Utility
FS APPLICATION
LREP GENENTECH, INC., 1 DNA WAY, SOUTH SAN FRANCISCO, CA, 94080

CLMN Number of Claims: 26
ECL Exemplary Claim: 1
DRWN 35 Drawing Page(s)
LN.CNT 4266
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to a method for the treatment of a cartilage disorder, including cartilage damaged by injury or degenerative cartilagenous disorders. The method involves contacting the cartilage with an IGF-1 analog with altered affinity for IGF-binding proteins (IGFBPs) or an IGFBP displacer peptide that prevents the interaction of an IGF with an IGFBP and does not bind to a human IGF receptor.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 48 OF 73 USPATFULL on STN
AN 2003:50839 USPATFULL
TI Methods for treating or reducing the risk of pain and inflammatory disorders by administering inhibitors of activated thrombin activatable fibrinolysis inhibitor
IN Gardell, Stephen J., Woodbridge, CT, UNITED STATES
Mao, Shi-Shan, North Wales, PA, UNITED STATES
PI US 20030035795 A1 20030220
AI US 2002-120323 A1 20020411 (10)
PRAI US 2001-283748P 20010413 (60)
DT Utility
FS APPLICATION
LREP MERCK AND CO INC, P O BOX 2000, RAHWAY, NJ, 070650907
CLMN Number of Claims: 22
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1448
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention includes methods for treating or reducing the risk of inflammation in a patient which comprises treating the patient with an inhibitor of activated thrombin activatable fibrinolysis inhibitor. Such diseases include but are not limited to nephritis, systemic lupus erythematosus, rheumatoid arthritis, glomerulonephritis, and sacoidosis. The invention includes methods for treating or reducing the risk of pain in a patient which comprises treating the patient with an inhibitor of activated thrombin activatable fibrinolysis inhibitor. In one class of these methods, the inhibitor of activated thrombin activatable fibrinolysis inhibitor is selected from the group consisting of 2-(6-amino-pyridin-3-ylmethyl)-3-butyl-succinic acid, 2-(6-amino-pyridin-3-ylmethyl)-3-phenethyl-succinic acid, 2-(6-amino-pyridin-3-ylmethyl)-3-methyl-succinic acid, 2-(6-amino-5-methyl-pyridin-3-ylmethyl)-3-[(1-benzyloxycarbonylamino-2-methyl-propyl)hydroxy-phosphinoyl]-propionic acid, 2-(6-amino-pyridin-3-ylmethyl)-3-[hydroxy-(3-phenyl-propyl)-phosphinoyl]-propionic acid, 2-(amino-pyridin-3-ylmethyl)-N-hydroxy-succinamic acid, 3-(6-amino-pyridin-3-yl)-2-mercaptomethyl-propionic acid, 2-(2-amino-pyridin-4-ylmethyl)-3-mercapto-propionic acid, 2-(6-amino-pyridin-3-ylmethyl)-2-mercaptomethyl-butyric acid, 3-(6-amino-5-methyl-pyridin-3-yl)-2-mercaptomethyl-2-methyl-propionic acid, 3-(6-amino-5-methyl-pyridin-3-yl)-2-mercaptomethyl-propionic acid, 3-(6-amino-4-methyl-pyridin-3-yl)-2-mercaptomethyl-propionic acid, and 3-(6-amino-pyridin-3-yl)-2-mercaptomethyl-butyric acid or a pharmaceutically acceptable salt thereof.

The invention is also a method for treating or reducing the risk of inflammation in a patient, or treating or reducing the risk of pain, which comprises treating the patient with a composition comprising an

inhibitor of activated thrombin activatable fibrinolysis inhibitor and an NSAID, e.g., a COX-2 inhibitor. Such diseases include but are not limited to nephritis, systemic lupus, erythematosus, rheumatoid arthritis, glomerulonephritis, and sacoidosis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 49 OF 73 USPATFULL on STN
AN 2003:11207 USPATFULL
TI Treating or preventing the early stages of degeneration of articular cartilage or subchondral bone in mammals using carprofen and derivatives
IN Evans, Nigel A., East Lyme, CT, UNITED STATES
Kilroy, Carolyn R., Old Lyme, CT, UNITED STATES
Lundy, Kristin M., Groton, CT, UNITED STATES
Pelletier, Jean-Pierre, St. Lambert, CANADA
Ricketts, Anthony P., Stonington, CT, UNITED STATES
PI US 20030008911 A1 20030109
AI US 2002-228626 A1 20020826 (10)
RLI Continuation of Ser. No. US 1999-283993, filed on 1 Apr 1999, PENDING
PRAI US 1998-86457P 19980522 (60)
DT Utility
FS APPLICATION
LREP KOHN & ASSOCIATES, PLLC, Suite 410, 30500 Northwestern Highway, Farmington Hills, MI, 48334
CLMN Number of Claims: 12
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2428
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Treating or preventing the early stages of degeneration of articular cartilage or subchondral bone in the affected joint of a mammal is accomplished by administering a chondroprotective compound of Formula (I): ##STR1##

where A is hydroxy, (C.sub.1-C.sub.4)alkoxy, amino, hydroxy-amino, mono-(C.sub.1-C.sub.2)alkylamino, di-(C.sub.1-C.sub.2)alkylamino; X and Y are independently H or (C.sub.1-C.sub.2)alkyl; and n is 1 or 2; R.sup.6 is halogen, (C.sub.1- C.sub.3)alkyl, trifluoromethyl, or nitro; R.sup.9 is H; (C.sub.1-C.sub.2)alkyl; phenyl or phenyl-(C.sub.1-C.sub.2)alkyl, where phenyl is optionally mono-substituted by fluoro or chloro; --C(.dbd.O)--R, where R is (C.sub.1-C.sub.2)alkyl or phenyl, optionally mono-substituted by fluoro or chloro; or --C(.dbd.O)--O--R.sup.1, where R.sup.1 is (C.sub.1- C.sub.2)alkyl.

This treatment ameliorates, diminishes, actively treats, reverses or prevents any injury, damage or loss of articular cartilage or subchondral bone subsequent to said early stage of said degeneration. Whether or not a mammal needs such treatment is determined by whether or not it exhibits a statistically significant deviation from normal standard values in synovial fluid or membrane from the affected joint, with respect to at least five of the following substances: increased interleukin-1 beta (IL-1β), increased tumor necrosis factor alpha (TNFα); increased ratio of IL-1β to IL-1 receptor antagonist protein (IRAP); increased expression of p55 TNF receptors (p55 TNF-R), increased interleukin-6 (IL-6); increased leukemia inhibitory factor (LIF); decreased insulin-like growth factor-1 (IGF-1); decreased transforming growth factor beta (TGFβ); decreased platelet-derived growth factor (PDGF); decreased basic fibroblast growth factor (b-FGF); increased keratan sulfate; increased stromelysin; increased ratio of stromelysin to tissue inhibitor of metalloproteases (TIMP); increased osteocalcin; increased alkaline phosphatase; increased cAMP responsive to hormone challenge; increased urokinase plasminogen activator (uPA);

increased cartilage oligomeric matrix protein; and increased collagenase.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 50 OF 73 USPATFULL on STN
AN 2002:336923 USPATFULL
TI Compositions and methods for treating inflammatory conditions utilizing protein or polysaccharide containing anti-microtubule agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
Toleikis, Philip M., Vancouver, CANADA
PA Angiotech Pharmaceuticals, Inc., Vancouver, CANADA, V6T 1Z4 (non-U.S. corporation)
PI US 20020192280 A1 20021219
AI US 2002-137736 A1 20020501 (10)
PRAI US 2001-288017P 20010501 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092
CLMN Number of Claims: 125
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3213
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed herein are compositions and methods for treating a variety of inflammatory conditions (e.g., inflammatory arthritis, adhesions, tumor excision sites, and fibroproliferative diseases of the eye). For example, there is provided a composition comprising a protein or polysaccharide containing dispersed (e.g., in micelle or liposome form) anti-microtubule agent, which may be formulated for administration to a patient in need thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 51 OF 73 USPATFULL on STN
AN 2002:199163 USPATFULL
TI Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents
IN Nakao, Kazunnari, Aichi-Ken, JAPAN
Okumura, Yoshiyuki, Aichi-Ken, JAPAN
Matsumizu, Miyako, Aichi-Ken, JAPAN
Ueno, Naomi, Aichi-Ken, JAPAN
Hashizume, Yoshinobu, Aichi-ken, JAPAN
Kato, Tomoki, Aichi-Ken, JAPAN
Kawai, Akiyoshi, Aichi-Ken, JAPAN
Miyake, Yoriko, Aichi-Ken, JAPAN
Nukui, Seiji, Aichi-Ken, JAPAN
Shinjyo, Katsuhiro, Aichi-Ken, JAPAN
Taniguchi, Kana, Aichi-Ken, JAPAN
PI US 20020107273 A1 20020808
US 6710054 B2 20040323
AI US 2001-977621 A1 20011015 (9)
PRAI US 2000-241825P 20001019 (60)
DT Utility
FS APPLICATION
LREP Paul H. Ginsburg, Pfizer Inc, 20th Floor, 235 East 42nd Street, New York, NY, 10017-5755
CLMN Number of Claims: 16
ECL Exemplary Claim: 1

DRWN No Drawings
LN.CNT 15933
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention provides a compound of the formula (I): ##STR1##

or the pharmaceutically acceptable salts thereof, wherein Y.sup.1, Y.sup.2, Y.sup.3 and Y.sup.4 are independently selected from N, CH, etc.; R.sup.1 is H, C.sub.1-8 alkyl, etc.; Q.sup.1 is a 5-12 membered monocyclic or bicyclic aromatic ring optionally containing up to 4 heteroatoms selected from O, N, and S, etc.; A is 5-6 membered monocyclic aromatic ring optionally containing up to 3 heteroatoms selected form O, N and S, etc.; B is C.sub.1-6 alkylene optionally substituted with an oxo group, etc.; W is NH, O, etc.; R.sup.2 is H, C.sub.1-4 alkyl, etc.; Z is a 5-12 membered monocyclic or bicyclic aromatic ring optionally containing up to 3 heteroatoms selected form O, N and S, etc.; L is halo, C.sub.1-4 alkyl, etc.; m is 0, 1 or 2; R.sup.3 and R .sup.4 are independently selected from H and C.sub.1-4 alkyl; R .sup.5 is H, C.sub.1-4 alkyl; etc.; Q.sup.2 is a 5-12 membered monocyclic or bicyclic aromatic ring or tricyclic ring optionally containing up to 3 heteroatoms selected from O, N and S, etc. These compounds are useful for the treatment of medical conditions mediated by prostaglamndin such as pain, fever or inflammation, etc. This invention also provides a pharmaceutical composition comprising the above compound.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 52 OF 73 USPATFULL on STN
AN 2002:165195 USPATFULL
TI Novel methods and reagents for the treatment of osteoarthritis
IN Warman, Matthew L., Cleveland, OH, UNITED STATES
Carpten, John D., Gaithersburg, MD, UNITED STATES
Trent, Jeffery M., Rockville, MD, UNITED STATES
Marcelino, Jose, South Euclid, OH, UNITED STATES
PA Case Western Reserve University, Cleveland, OH, UNITED STATES, 44106 (U.S. corporation)
PI US 20020086824 A1 20020704
AI US 2001-802207 A1 20010308 (9)
RLI Continuation of Ser. No. US 2000-619175, filed on 19 Jul 2000, PENDING
PRAI US 1999-145328P 19990723 (60)
DT Utility
FS APPLICATION
LREP Peter G. Carroll, MEDLEN & CARROLL, LLP, Suite 350, 101 Howard Street, San Francisco, CA, 94104
CLMN Number of Claims: 9
ECL Exemplary Claim: 1
DRWN 5 Drawing Page(s)
LN.CNT 1426
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods and compositions are described for treating osteoarthritis. Treatment is described with a new class of anti-OA drug, namely compounds that may be used as lubricants of the tissue diagnosed with OA. Additionally, the present invention provides reagents for the screening of compounds that may be used as therapeutic agents in the treatment of OA.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 53 OF 73 USPATFULL on STN
AN 2002:133860 USPATFULL
TI Chondroprotective/restorative compositions and methods of use thereof
IN Pierce, Scott W., Lexington, KY, UNITED STATES

PI US 20020068718 A1 20020606
US 6924273 B2 20050802
AI US 2001-967977 A1 20011002 (9)
PRAI US 2000-237838P 20001003 (60)
DT Utility
FS APPLICATION
LREP Isaac A. Angres, Suite 301, 2001 Jefferson Davis Highway, Arlington, VA, 22202
CLMN Number of Claims: 38
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1312
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The instant invention provides a method of treating or preventing osteoarthritis, joint effusion, joint inflammation and pain, synovitis, lameness, post operative arthroscopic surgery, deterioration of proper joint function including joint mobility, the reduction or inhibition of metabolic activity of chondrocytes, the activity of enzymes that degrade cartilage, the reduction or inhibition of the production of Hyaluronic acid, said method comprising orally administering to a mammalian species a therapeutically effective amount of Hyaluronic Acid or pharmaceutically acceptable salts thereof. Additionally, compositions containing hyaluronic acid; chondroitin sulfate, and glucosamine sulfate in a paste formulation are also disclosed which can be administered on their own or can be used as a feed additive.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 54 OF 73 USPATFULL on STN
AN 2002:16578 USPATFULL
TI Composition and method for treating inflammatory diseases
IN Boone, Thomas C., Newbury Park, CA, UNITED STATES
Hershenson, Susan, Newbury Park, CA, UNITED STATES
Bevilacqua, Michael P., Boulder, CO, UNITED STATES
Collins, David S., Fishers, IN, UNITED STATES
PA Amgen Inc. (U.S. corporation)
PI US 20020009454 A1 20020124
US 6733753 B2 20040511
AI US 2001-784623 A1 20010215 (9)
RLI Division of Ser. No. US 1998-131247, filed on 7 Aug 1998, PENDING
PRAI WO 1997-US2131 19970210
US 1997-55185P 19970808 (60)
DT Utility
FS APPLICATION
LREP Timothy J. Gaul, U.S. Patent Operations/TJG, Dept. 4300, M/S 27-4-A, AMGEN, INC., One Amgen Center Drive, Thousand Oaks, CA, 91320-1799
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 14 Drawing Page(s)
LN.CNT 3525
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A protein which exhibits a therapeutic effect on inflammation and is useful for treating IL-1-mediated inflammatory diseases, particularly diseases of the joint.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 55 OF 73 USPATFULL on STN
AN 2001:182597 USPATFULL
TI Method for treating inflammatory diseases by administering a thrombin inhibitor

IN Shafer, Jules, Gwynedd Valley, PA, United States
Visco, Denise M., Fanwood, NJ, United States
PI US 20010031757 A1 20011018
US 6362190 B2 20020326
AI US 2001-853057 A1 20010510 (9)
RLI Division of Ser. No. US 1999-407821, filed on 28 Sep 1999, GRANTED, Pat. No. US 6232315
PRAI US 1998-102020P 19980928 (60)
DT Utility
FS APPLICATION
LREP MERCK AND CO INC, P O BOX 2000, RAHWAY, NJ, 070650907
CLMN Number of Claims: 9
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1327
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention is a method for treating an inflammatory disease in a patient which comprises treating the patient with a composition comprising a thrombin inhibitor. Such diseases include but are not limited to nephritis, systemic lupus erythematosus, rheumatoid arthritis, glomerulonephritis, and sacoidosis. In one class of the method, the thrombin inhibitor is selected from the group consisting of 3-(2-phenylethylamino)-6-methyl-1-(2-amino-6-methyl-5-methylene-carboxamidomethylpyridinyl)-2-pyrazinone, N'-[[1-(aminoiminomethyl)-4-piperidinyl]methyl]-N-(3,3-diphenylpropionyl)-L-proline amide, and 3-(2-phenethylamino)-6-methyl-1-(2-amino-6-methyl-5-methylenecarboxamidomethylpyridinyl)-2-pyridinone or a pharmaceutically acceptable salt thereof.

The invention is also a method for treating an inflammatory disease in a patient which comprises treating the patient with a composition comprising a thrombin inhibitor and an NSAID, e.g., a COX-2 inhibitor. Such diseases include but are not limited to nephritis, systemic lupus, erythematosus, rheumatoid arthritis, glomerulonephritis, and sacoidosis. In one class of the method, the thrombin inhibitor is selected from the group consisting of 3-(2-phenylethylamino)-6-methyl-1-(2-amino-6-methyl-5-methylene-carboxamidomethylpyridinyl)-2-pyrazinone, N'-[[1-(aminoiminomethyl)-4-piperidinyl]methyl] -N-(3,3-diphenylpropionyl)-L-proline amide, and 3-(2-phenethylamino)-6-methyl-1-(2-amino-6-methyl-5-methylenecarboxamidomethylpyridinyl)-2-pyridinone or a pharmaceutically acceptable salt thereof and the COX-2 inhibitor is 3-phenyl-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone or a pharmaceutically acceptable salt thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 56 OF 73 USPATFULL on STN
AN 2001:162845 USPATFULL
TI Composition and method for treating inflammatory diseases
IN Boone, Thomas C., Newbury Park, CA, United States
Hershenson, Susan, Newbury Park, CA, United States
Bevilacqua, Michael P., Boulder, CO, United States
Collins, David S., Fishers, IN, United States
PA Amgen Inc., Thousand Oaks, CA, United States (U.S. corporation)
PI US 6294170 B1 20010925
AI US 1998-131247 19980807 (9)
PRAI US 1997-55185P 19970808 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Born, Michael
LREP Gaul, Timothy J., Levy, Ron K., Odre, Steven M.
CLMN Number of Claims: 15

ECL Exemplary Claim: 1
DRWN 14 Drawing Figure(s); 14 Drawing Page(s)
LN.CNT 3022
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A protein which exhibits a therapeutic effect on inflammation and is useful for treating IL-1-mediated inflammatory diseases, particularly diseases of the joint.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 57 OF 73 USPATFULL on STN
AN 2001:90257 USPATFULL
TI TREATING OR PREVENTING THE EARLY STAGES OF DEGENERATION OF ARTICULAR CARTILAGE OR SUBCHONDRAL BONE IN MAMMALS USING CARPROFEN AND DERIVATIVES
IN EVANS, NIGEL A, EAST LYME, CT, United States
KILROY, CAROLYN R, OLD LYME, CT, United States
LUNDY, KRISTIN M, GROTON, CT, United States
JEAN-PIERRE, PELLETIER, ST LAMBERT, Canada
PI US 20010002401 A1 20010531
US 6506785 B2 20030114
AI US 1999-283993 A1 19990401 (9)
DT Utility
FS APPLICATION
LREP PFIZER INC, 235 E 42ND STREET, NEW YORK, NY, 10017
CLMN Number of Claims: 12
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2422
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Treating or preventing the early stages of degeneration of articular cartilage or subchondral bone in the affected joint of a mammal is accomplished by administering a chondroprotective compound of Formula (I): ##STR1##

where A is hydroxy, (C.sub.1-C.sub.4)alkoxy, amino, hydroxy-amino, mono-(C.sub.1-C.sub.2)alkylamino, di-(C.sub.1-C.sub.2)alkylamino; X and Y are independently H or (C.sub.1-C.sub.2)alkyl; and n is 1 or 2; R.sup.6 is halogen, (C.sub.1-C.sub.3)alkyl, trifluoromethyl, or nitro; R.sup.9 is H; (C.sub.1-C.sub.2)alkyl; phenyl or phenyl-(C.sub.1-C.sub.2)alkyl, where phenyl is optionally mono-substituted by fluoro or chloro; --C(.dbd.O)-R, where R is (C.sub.1-C.sub.2)alkyl or phenyl, optionally mono-substituted by fluoro or chloro; or --C(.dbd.O)--O-R', where R.sup.1 is (C.sub.1-C.sub.2)alkyl.

This treatment ameliorates, diminishes, actively treats, reverses or prevents any injury, damage or loss of articular cartilage or subchondral bone subsequent to said early stage of said degeneration. Whether or not a mammal needs such treatment is determined by whether or not it exhibits a statistically significant deviation from normal standard values in synovial fluid or membrane from the affected joint, with respect to at least five of the following substances: increased interleukin-1 beta (IL-1β); increased tumor necrosis factor alpha (TNFα); increased ratio of IL-1β to IL-1 receptor antagonist protein (IRAP); increased expression of p55 TNF receptors (p55 TNF-R); increased interleukin-6 (IL-6); increased leukemia inhibitory factor (LIF); decreased insulin-like growth factor-1 (IGF-1); decreased transforming growth factor beta (TGFβ); decreased platelet-derived growth factor (PDGF); decreased basic fibroblast growth factor (b-FGF); increased keratan sulfate; increased stromelysin; increased ratio of stromelysin to tissue inhibitor of metalloproteases (TIMP); increased osteocalcin; increased alkaline phosphatase; increased cAMP responsive to hormone challenge; increased urokinase plasminogen activator (uPA);

increased cartilage oligomeric matrix protein; and increased collagenase.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 58 OF 73 USPATFULL on STN
AN 2001:71550 USPATFULL
TI Method for treating inflammatory diseases by administering a thrombin inhibitor
IN Shafer, Jules, Gwynedd Valley, PA, United States .
Visco, Denise M., Fanwood, NJ, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 6232315 B1 20010515
AI US 1999-407821 19990928 (9)
PRAI US 1998-102P 19980928 (60)
DT Utility
FS Granted
EXNAM Primary Examiner: Spivack, Phyllis G.
LREP Parr, Richard S., Winokur, Melvin
CLMN Number of Claims: 7
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1330
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention is a method for treating an inflammatory disease in a patient which comprises treating the patient with a composition comprising a thrombin inhibitor. Such diseases include but are not limited to nephritis, systemic lupus erythematosus, rheumatoid arthritis, glomerulonephritis, and sacoidosis. In one class of the method, the thrombin inhibitor is selected from the group consisting of 3-(2-phenylethylamino)-6-methyl-1-(2-amino-6-methyl-5-methylenecarboxamidomethylpyridinyl)-2-pyrazinone, N'-[[1-(aminoiminomethyl)-4-piperidinyl]methyl]-N-(3,3-diphenylpropionyl)-L-proline amide, and 3-(2-phenethylamino)-6-methyl-1-(2-amino-6-methyl-5-methylenecarboxamidomethylpyridinyl)-2-pyridinone or a pharmaceutically acceptable salt thereof.

The invention is also a method for treating an inflammatory disease in a patient which comprises treating the patient with a composition comprising a thrombin inhibitor and an NSAID, e.g., a COX-2 inhibitor. Such diseases include but are not limited to nephritis, systemic lupus, erythematosus, rheumatoid arthritis, glomerulonephritis, and sacoidosis. In one class of the method, the thrombin inhibitor is selected from the group consisting of 3-(2-phenylethylamino)-6-methyl-1-(2-amino-6-methyl-5-methylene-carboxamidomethylpyridinyl)-2-pyrazinone, N'-[[1-(aminoiminomethyl)-4-piperidinyl]methyl]-N-(3,3-diphenylpropionyl)-L-proline amide, and 3-(2-phenethylamino)-6-methyl-1-(2-amino-6-methyl-5-methylenecarboxamidomethylpyridinyl)-2-pyridinone or a pharmaceutically acceptable salt thereof and the COX-2 inhibitor is 3-phenyl-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone or a pharmaceutically acceptable salt thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 59 OF 73 USPATFULL on STN
AN 2000:98413 USPATFULL
TI Composition and method for treating inflammatory diseases
IN Collins, David S., Lafayette, CO, United States
Bevilacqua, Michael P., Boulder, CO, United States
PA Amgen Inc., Thousand Oaks, CA, United States (U.S. corporation)
PI US 6096728 20000801
AI US 1997-798414 19970207 (8)

PRAI US 1996-11419P 19960209 (60)
      US 1996-32789P 19961206 (60)
      US 1997-36241P 19970123 (60)
      US 1996-21443P 19960709 (60)
      US 1996-36534P 19961206 (60)
      US 1997-37737P 19970123 (60)
      US 1997-39314P 19970207 (60)
DT   Utility
FS   Granted
EXNAM Primary Examiner: Criares, Theodore J.
LREP Zindrick, Thomas D., Odre, Steven M., Levy, Ron K.
CLMN Number of Claims: 20
ECL   Exemplary Claim: 1
DRWN 5 Drawing Figure(s); 5 Drawing Page(s)
LN.CNT 2432
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB   A pharmaceutical composition comprising (a) an effective amount of controlled release polymer and (b) an effective amount of a proteinaceous IL-1 inhibitor. The composition exhibits a therapeutic effect on inflammation and is useful for treating IL-1 mediated inflammatory diseases, particularly diseases of the joint.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 60 OF 73 USPATFULL on STN
AN   97:83597 USPATFULL
TI   Compounds, compositions and methods for binding bio-affecting substances to surface membranes of bio-particles
IN   Kopia, Gregory A., Phoenixville, PA, United States
      Horan, Paul K., Downingtown, PA, United States
      Gray, Brian D., Ardmore, PA, United States
      Troutner, David E., Phoenixville, PA, United States
      Muirhead, Katharine A., West Chester, PA, United States
      Sheth, Kamleshkumar A., Downingtown, PA, United States
      Lin, Chia-En, Norristown, PA, United States
      Yu, Zhizhou, Jeffersonville, PA, United States
      Jensen, Bruce D., Collegeville, PA, United States
      Slezak, Sue Ellen, Downingtown, PA, United States
PA   Zynaxis, Inc., Malvern, PA, United States (U.S. corporation)
PI   US 5667764 19970916
AI   US 1992-884432 19920515 (7)
RLI   Continuation-in-part of Ser. No. US 1988-189192, filed on 2 May 1988, now abandoned
DT   Utility
FS   Granted
EXNAM Primary Examiner: Kight, John; Assistant Examiner: Chapman, Lara E.
LREP Dann, Dorfman, Herrell and Skillman
CLMN Number of Claims: 12
ECL   Exemplary Claim: 1
DRWN 12 Drawing Figure(s); 6 Drawing Page(s)
LN.CNT 3547
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB   Compounds are provided having the capability of binding therapeutically active substances to lipid containing bio-compatible particles , such as cells or viruses. These compounds include a bio-affecting moiety, comprising a therapeutically active substance, which is linked via a linking moiety to at least one hydrocarbon substituent selected so that the compounds is sufficiently non-polar to impart lipid binding capability to the compound. Thus, compounds of the invention are useful for site-selective delivery of therapeutic agents, and retention thereof at the selected site.

Methods are provided for using various compounds of the invention in treatment of diseases or other pathological conditions. For example, methods are provided for treatment of: (1) post-angioplasty restenosis; (2) rheumatoid arthritis; (3) tumor cell proliferation, particularly tumor cells associated with ovarian cancer; and (4) psoriasis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 61 OF 73 USPAT2 on STN
AN 2005:23953 USPAT2
TI Nutraceuticals for the treatment, protection and restoration of connective tissues
IN Shen, Bojang, Berala, AUSTRALIA
Ghosh, Peter, Fairlight, AUSTRALIA
PA Institute of Nutraceutical Research PTY Ltd., New South Wales, AUSTRALIA (non-U.S. corporation)
PI US 7371820 B2 20080513
AI US 2004-896546 20040722 (10)
RLI Continuation-in-part of Ser. No. WO 2003-AU61, filed on 23 Jan 2003, PENDING
PRAI AU 2002-112 20020123
AU 2002-1054 20020312
DT Utility
FS GRANTED
EXNAM Primary Examiner: Carlson, Karen Cochrane; Assistant Examiner: Rooke, Agnes B.
LREP Frommer Lawrence & Haug LLP, Kowalski, Thomas J., Collison, Angela M.
CLMN Number of Claims: 11
ECL Exemplary Claim: 1
DRWN 35 Drawing Figure(s); 35 Drawing Page(s)
LN.CNT 2337
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to a method for isolating from connective tissue a variety of glycosaminoglycan (GAG)-polypeptide complexes and polypeptides which are substantially free of contaminating DNA and other molecules such as viruses which may be associated with the DNA in the cell. The invention also relates to uses of GAG-peptide complexes and polypeptides substantially free of DNA either directly, or after further processing, for the treatment, protection and restoration of connective tissues in inflammatory and degenerative disorders such as rheumatoid arthritis and osteoarthritis in any of their multiple forms or other degenerative conditions in mammals.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 62 OF 73 USPAT2 on STN
AN 2004:233985 USPAT2
TI Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents
IN Nakao, Kazunari, Aichi-ken, JAPAN
Okumura, Yoshiyuki, Aichi-ken, JAPAN
Matsumizu, Miyako, Aichi-ken, JAPAN
Ueno, Naomi, Aichi-ken, JAPAN
Hashizume, Yoshinobu, Aichi-ken, JAPAN
Kato, Tomoki, Aichi-ken, JAPAN
Kawai, Akiyoshi, Aichi-ken, JAPAN
Miyake, Yoriko, Aichi-ken, JAPAN
Nukui, Seiji, Aichi-ken, JAPAN
Shinjyo, Katsuhiro, Aichi-ken, JAPAN
Taniguchi, Kana, Aichi-ken, JAPAN
PA Pfizer Inc., New York, NY, UNITED STATES (U.S. corporation)
PI US 7141580 B2 20061128

AI US 2004-771696 20040204 (10)
RLI Division of Ser. No. US 2001-977621, filed on 15 Oct 2001, Pat. No. US 6710054
PRAI US 2000-421825P 20001019 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Stockton, Laura L.
LREP Ashbrook, Charles W., Kurlandsky, David R.
CLMN Number of Claims: 12
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 15185
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention provides a compound of the formula (I):

##STR1## or the pharmaceutically acceptable salts thereof, wherein Y.sup.1, Y.sup.2, Y.sup.3 and Y.sup.4 are independently selected from N, CH, etc.; R.sup.1 is H, C.sub.1-8 alkyl, etc.; Q.sup.1 is a 5-12 membered monocyclic or bicyclic aromatic ring optionally containing up to 4 heteroatoms selected from O, N and S, etc.; A is a 5-6 membered monocyclic aromatic ring optionally containing up to 3 heteroatoms selected from O, N and S, etc.; B is C.sub.1-6 alkylene optionally substituted with an oxo group, etc.; W is NH, O, etc.; R.sup.2 is H, C.sub.1-4 alkyl, etc.; Z is a 5-12 membered monocyclic or bicyclic aromatic ring optionally containing up to 3 heteroatoms selected from O, N and S, etc.; L is halo, C.sub.1-4 alkyl, etc.; m is 0, 1 or 2; R.sup.3 and R.sup.4 are independently selected from H and C.sub.1-4 alkyl; R.sup.5 is H, C.sub.1-4 alkyl, etc.; Q.sup.2 is a 5-12 membered monocyclic or bicyclic aromatic ring or tricyclic ring optionally containing up to 3 heteroatoms selected from O, N and S, etc. These compounds are useful for the treatment of medical conditions mediated by prostaglamndin such as pain, fever or inflammation, etc. This invention also provides a pharmaceutical composition comprising the above compound.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 63 OF 73 USPAT2 on STN
AN 2004:190672 USPAT2
TI Methods and compositions for treatment of inflammatory disease
IN Levin, Bruce, Philadelphia, PA, UNITED STATES
PA Levin, Bruce H., Merion, PA, UNITED STATES (U.S. individual)
PI US 7112578 B2 20060926
AI US 2004-756695 20040112 (10)
RLI Continuation of Ser. No. US 2000-724645, filed on 28 Nov 2000, Pat. No. US 6677321
DT Utility
FS GRANTED
EXNAM Primary Examiner: Tucker, Zachary C.
LREP Kenyon & Kenyon LLP
CLMN Number of Claims: 18
ECL Exemplary Claim: 3
DRWN No Drawings
LN.CNT 667
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions useful for treating inflammatory diseases including arthritis are disclosed which comprise cetyl myristoleate compounds or related compounds and at least one compound useful for treatment of inflammatory disease, such as tetracycline compounds, Cox-2 inhibitors, non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, local anaesthetics, chelating agents, matrix metalloprotease inhibitors, inhibitors of inflammatory cytokines, glucosamine,

chondroitin sulfate and collagen hydrolysate. Also disclosed are pharmaceutical compositions and methods of treatment for inflammatory disease and local inflammation and dermal irritation. Also disclosed are compositions including tetracycline and at least one compound useful for treatment of inflammatory disease.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 64 OF 73 USPAT2 on STN
AN 2004:121064 USPAT2
TI Composition and method for treatment and prevention of traumatic synovitis and damage to articular cartilage
IN Marcum, Frank D., P.O. Box 13083, Lexington, KY, UNITED STATES 40583-3083
PI US 6979679 B2 20051227
AI US 2003-686918 20031016 (10)
PRAI US 2003-487681P 20030716 (60)
US 2002-419009P 20021016 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Wilson, James O.; Assistant Examiner: White, Everett
LREP Seanor, DVM., J. W.
CLMN Number of Claims: 26
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 817
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides compositions useful for the treatment and/or prevention of damage to diarthrodial (synovial) joints and, in particular, traumatic synovitis, inflammation of the synovial membrane, and damage to the articular cartilage of the joint. Specifically, provided are compositions specially formulated for intra-articular and/or parenteral use in the treatment and/or prevention of traumaticsynovitis and/or damage to articular cartilage. Compositions adapted specifically for post surgical joint lavage or treatment and/or prevention of inflammatory arthritis, osteoarthritis (OA) and/or degenerative joint disease (DJD) are also provided. Compositions adapted for intra-articular and/or systemic administration comprised of therapeutic amounts of: chondroitin sulfate; N-acetyl D-glucosamine; and hyaluronan (hyaluronic acid) are provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 65 OF 73 USPAT2 on STN
AN 2003:334713 USPAT2
TI Compositions and methods for systemic inhibition of cartilage degradation
IN Demopulos, Gregory A., Mercer Island, WA, UNITED STATES
Palmer, Pamela Pierce, San Francisco, CA, UNITED STATES
Herz, Jeffrey M., Mill Creek, WA, UNITED STATES
PA Omeros Corporation, Seattle, WA, UNITED STATES (U.S. corporation)
PI US 7067144 B2 20060627
AI US 2003-356649 20030131 (10)
RLI Continuation-in-part of Ser. No. US 1998-31546, ABANDONED A 371 of International Ser. No. WO 2000-US19864, filed on 21 Jul 2000 Continuation-in-part of Ser. No. US 2001-839633, filed on 20 Apr 2001, ABANDONED Continuation-in-part of Ser. No. WO 1999-US26330, filed on 5 Nov 1999, ABANDONED
PRAI US 2002-353552P 20020201 (60)
US 1999-144904P 19990721 (60)
US 1998-107256P 19981105 (60)

DT Utility
FS GRANTED
EXNAM Primary Examiner: Azpuru, Carlos A.
LREP Omeros Corporation, Kelbon, Marcia S.
CLMN Number of Claims: 41
ECL Exemplary Claim: 1
DRWN 9 Drawing Figure(s); 9 Drawing Page(s)
LN.CNT 6202
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods and compositions for inhibiting articular cartilage degradation. The compositions preferably include multiple chondroprotective agents, including at least one agent that promotes cartilage anabolic activity and at least one agent that inhibits cartilage catabolism. The compositions may also include one or more pain and inflammation inhibitory agents. The compositions may be administered systemically, such as to treat patients at risk of cartilage degradation at multiple joints, and suitably may be formulated in a carrier or delivery vehicle that is targeted to the joints. Alternatively the compositions may be injected or infused directly into the joint.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 66 OF 73 USPAT2 on STN
AN 2003:300766 USPAT2
TI Method for treating cartilage disorders
IN Chen, Yvonne Man-Yee, San Mateo, CA, UNITED STATES
Clark, Ross G., Auckland, NEW ZEALAND
Cochran, Andrea G., San Francisco, CA, UNITED STATES
Dubaquie, Yves, Lawrenceville, NJ, UNITED STATES
Fielder, Paul J., Redwood City, CA, UNITED STATES
Filvaroff, Ellen, San Francisco, CA, UNITED STATES
Lowman, Henry B., El Granada, CA, UNITED STATES
Mortensen, Deborah L., Pacifica, CA, UNITED STATES
Robinson, Iain C. A. F., St. Albans, UNITED KINGDOM
Skelton, Nicholas J., San Mateo, CA, UNITED STATES
PA Genentech, Inc., South San Francisco, CA, UNITED STATES (U.S. corporation)
PI US 7423017 B2 20080909
AI US 2002-271869 20021016 (10)
RLI Continuation of Ser. No. US 2001-858935, filed on 16 May 2001, ABANDONED Continuation-in-part of Ser. No. US 2000-477923, filed on 5 Jan 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-477924, filed on 5 Jan 2000, Pat. No. US 6403764 Continuation-in-part of Ser. No. US 1999-337227, filed on 22 Jun 1999, Pat. No. US 6420518 Continuation-in-part of Ser. No. US 1998-52888, filed on 31 Mar 1998, Pat. No. US 6251865 Continuation-in-part of Ser. No. US 1997-825852, filed on 4 Apr 1997, Pat. No. US 6121416
PRAI US 2000-248985P 20001115 (60)
US 2000-204490P 20000516 (60)
US 1999-170261P 19991209 (60)
US 1999-115010P 19990106 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Robinson, Hope A
LREP Kresnak, Mark T., Dreger, Esq., Ginger R., Goodwin Procter LLP
CLMN Number of Claims: 8
ECL Exemplary Claim: 1
DRWN 63 Drawing Figure(s); 35 Drawing Page(s)
LN.CNT 6112
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to a method for the treatment of a cartilage disorder, including cartilage damaged by injury or

degenerative cartilagenous disorders. The method involves contacting the cartilage with an IGF-1 analog with altered affinity for IGF-binding proteins (IGFBPs) or an IGFBP displacer peptide that prevents the interaction of an IGF with an IGFBP and does not bind to a human IGF receptor.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 67 OF 73 USPAT2 on STN
AN 2003:294879 USPAT2
TI Selective inhibitors of cyclooxygenase-2
IN DeMello, Kristin Lundy, Ledyard, CT, United States
Bronk, Brian S., Gales Ferry, CT, United States
Crosson, Rhonda Marie, Ann Arbor, MI, United States
PA Pfizer Inc., New York, NY, United States (U.S. corporation)
PI US 6846818 B2 20050125
AI US 2003-414856 20030416 (10)
PRAI US 2002-374372P 20020422 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Shah, Mukund J.; Assistant Examiner: Habte, Kahsay
LREP Richardson, Peter C., Wootton, Thomas A., Hosley, Mary J.
CLMN Number of Claims: 25
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 2060
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to cyclooxygenase-2 (COX-2) selective inhibitors of formula I: ##STR1##

pharmaceutical compositions containing them, to their medicinal use, and to their preparations. The compounds of the invention are particularly useful in the treatment or alleviation of inflammation and inflammation associated disorders, such as, for example, rheumatoid arthritis and osteoarthritis, and in the relief of pain, such as, for example, pain associated with surgery or trauma, in mammals, preferably felines and canines.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 68 OF 73 USPAT2 on STN
AN 2002:199163 USPAT2
TI Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents
IN Nakao, Kazunari, Aichi-Ken, JAPAN
Okumura, Yoshiyuki, Aichi-Ken, JAPAN
Matsumizu, Miyako, Aichi-Ken, JAPAN
Ueno, Naomi, Aichi-Ken, JAPAN
Hashizume, Yoshinobu, Aichi-Ken, JAPAN
Kato, Tomoki, Aichi-Ken, JAPAN
Kawai, Akiyoshi, Aichi-Ken, JAPAN
Miyake, Yoriko, Aichi-Ken, JAPAN
Nukui, Seiji, Aichi-Ken, JAPAN
Shinjyo, Katsuhiro, Aichi-Ken, JAPAN
Taniguchi, Kana, Aichi-Ken, JAPAN
PA Pfizer Inc, New York, NY, United States (U.S. corporation)
PI US 6710054 B2 20040323
AI US 2001-977621 20011015 (9)
PRAI US 2000-241825P 20001019 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Stockton, Laura L.

LREP Ashbrook, Charles W., Kurlandsky, David R.
CLMN Number of Claims: 16
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 15319
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention provides a compound of the formula (I): ##STR1##

or the pharmaceutically acceptable salts thereof, wherein Y.sup.1, Y.sup.2, Y.sup.3 and Y.sup.4 are independently selected from N, CH, etc.; R.sup.1 is H, C.sub.1-8 alkyl, etc.; Q.sup.1 is a 5-12 membered monocyclic or bicyclic aromatic ring optionally containing up to 4 heteroatoms selected from O, N, and S, etc.; A is 5-6 membered monocyclic aromatic ring optionally containing up to 3 heteroatoms selected form O, N and S, etc.; B is C.sub.1-6 alkylene optionally substituted with an oxo group, etc.; W is NH, O, etc.; R.sup.2 is H, C.sub.1-4 alkyl, etc.; Z is a 5-12 membered monocyclic or bicyclic aromatic ring optionally containing up to 3 heteroatoms selected form O, N and S, etc.; L is halo, C.sub.1-4 alkyl, etc.; m is 0, 1 or 2; R.sup.3 and R.sup.4 are independently selected from H and C.sub.1-4 alkyl; R.sup.5 is H, C.sub.1-4 alkyl; etc.; Q.sup.2 is a 5-12 membered monocyclic or bicyclic aromatic ring or tricyclic ring optionally containing up to 3 heteroatoms selected from O, N and S, etc. These compounds are useful for the treatment of medical conditions mediated by prostaglamndin such as pain, fever or inflammation, etc. This invention also provides a pharmaceutical composition comprising the above compound.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 69 OF 73 USPAT2 on STN
AN 2002:133860 USPAT2
TI Chondroprotective/restorative compositions and methods of use thereof
IN Pierce, Scott W., 1072 Heather Gate Ct., Lexington, KY, UNITED STATES 40511
PI US 6924273 B2 20050802
AI US 2001-967977 20011002 (9)
PRAI US 2000-237838P 20001003 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Wilson, James O.; Assistant Examiner: Khare, Devesh
LREP Angres, Isaac A., Petraglia, Susan P.
CLMN Number of Claims: 28
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 1314
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The instant invention provides a method of treating or preventing osteoarthritis, joint effusion, joint inflammation and pain, synovitis, lameness, post operative arthroscopic surgery, deterioration of proper joint function including joint mobility, the reduction or inhibition of metabolic activity of chondrocytes, the activity of enzymes that degrade cartilage, the reduction or inhibition of the production of Hyaluronic acid, said method comprising orally administering to a mammalian species a therapeutically effective amount of Hyaluronic Acid or pharmaceutically acceptable salts thereof. Additionally, compositions containing hyaluronic acid; chondroitin sulfate, and glucosamine sulfate in a paste formulation are also disclosed which can be administered on their own or can be used as a feed additive.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 70 OF 73 USPAT2 on STN
AN 2002:16578 USPAT2
TI Composition and method for treating inflammatory diseases
IN Boone, Thomas C., Newbury Park, CA, United States
Hershenson, Susan, Newbury Park, CA, United States
Bevilacqua, Michael P., Boulder, CO, United States
Collins, David S., Fishers, IN, United States
PA Amgen Inc., Thousand Oaks, CA, United States (U.S. corporation)
PI US 6733753 B2 20040511
AI US 2001-784623 20010215 (9)
RLI Continuation of Ser. No. US 1998-131247, filed on 7 Aug 1998, now patented, Pat. No. US 6294170 Continuation of Ser. No. WO 1997-US2131, filed on 10 Feb 1997
PRAI US 1997-55185P 19970808 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Borin, Michael
LREP Finnegan, Henderson, Farabow, Garrett & Dunner, LLP
CLMN Number of Claims: 16
ECL Exemplary Claim: 1
DRWN 14 Drawing Figure(s); 14 Drawing Page(s)
LN.CNT 3865
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A protein which exhibits a therapeutic effect on inflammation and is useful for treating IL-1-mediated inflammatory diseases, particularly diseases of the joint.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 71 OF 73 USPAT2 on STN
AN 2001:182597 USPAT2
TI Method for treating inflammatory diseases by administering a thrombin inhibitor
IN Shafer, Jules, Gwynedd Valley, PA, United States
Visco, Denise M., Fanwood, NJ, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 6362190 B2 20020326
AI US 2001-853057 20010510 (9)
RLI Division of Ser. No. US 1999-407821, filed on 28 Sep 1999, now patented, Pat. No. US 6232315
PRAI US 1998-102020P 19980928 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Spivack, Phyllis G.
LREP Parr, Richard S., Winokur, Melvin
CLMN Number of Claims: 2
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 1242
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention is a method for treating an inflammatory disease in a patient which comprises treating the patient with an oral composition comprising a thrombin inhibitor. Such diseases include but are not limited to nephritis, systemic lupus erythematosus, rheumatoid arthritis, glomerulonephritis and sarcoidosis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 72 OF 73 USPAT2 on STN
AN 2001:90257 USPAT2
TI Treating or preventing the early stages of degeneration of articular

cartilage or subchondral bone in mammals using carprofen and derivatives
IN Evans, Nigel A., East Lyme, CT, United States
Kilroy, Carolyn R., Old Lyme, CT, United States
Lundy, Kristin M., Groton, CT, United States
Pelletier, Jean-Pierre, St. Lambert, CANADA
Ricketts, Anthony P., Stonington, CT, United States
PA Pfizer, Inc., New York, NY, United States (U.S. corporation)
PI US 6506785 B2 20030114
AI US 1999-283993 19990401 (9)
PRAI US 1998-86457P 19980522 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Criares, Theodore J.
LREP Kohn & Associates, PLLC, Ginsburg, Paul H., Ling, Lorraine B.
CLMN Number of Claims: 6
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 2372
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Treating or preventing the early stages of degeneration of articular cartilage or subchondral bone in the affected joint of a mammal is accomplished by administering a chondroprotective compound of Formula (I): ##STR1##

where A is hydroxy, (C.sub.1-C.sub.4)alkoxy, amino, hydroxy-amino, mono-(C.sub.1-C.sub.2)alkylamino, di-(C.sub.1-C.sub.2)alkylamino; X and Y are independently H or (C.sub.1-C.sub.2)alkyl; and n is 1 or 2; R.sup.6 is halogen, (C.sub.1-C.sub.3)alkyl, trifluoromethyl, or nitro; R.sup.9 is H; (C.sub.1-C.sub.2)alkyl; phenyl or phenyl-(C.sub.1-C.sub.2)alkyl, where phenyl is optionally mono-substituted by fluoro or chloro; --C(.dbd.O)--R, where R is (C.sub.1-C.sub.2)alkyl or phenyl, optionally mono-substituted by fluoro or chloro; or --C(.dbd.O)--O--R', where R.sup.1 is (C.sub.1-C.sub.2)alkyl.

This treatment ameliorates, diminishes, actively treats, reverses or prevents any injury, damage or loss of articular cartilage or subchondral bone subsequent to said early stage of said degeneration. Whether or not a mammal needs such treatment is determined by whether or not it exhibits a statistically significant deviation from normal standard values in synovial fluid or membrane from the affected joint, with respect to at least five of the following substances: increased interleukin-1 beta (IL-1β); increased tumor necrosis factor alpha (TNFα); increased ratio of IL-1β to IL-1 receptor antagonist protein (IRAP); increased expression of p55 TNF receptors (p55 TNF-R); increased interleukin-6 (IL-6); increased leukemia inhibitory factor (LIF); decreased insulin-like growth factor-1 (IGF-1); decreased transforming growth factor beta (TGFβ); decreased platelet-derived growth factor (PDGF); decreased basic fibroblast growth factor (b-FGF); increased keratan sulfate; increased stromelysin; increased ratio of stromelysin to tissue inhibitor of metalloproteases (TIMP); increased osteocalcin; increased alkaline phosphatase; increased cAMP responsive to hormone challenge; increased urokinase plasminogen activator (uPA); increased cartilage oligomeric matrix protein; and increased collagenase.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 73 OF 73 WPINDEX COPYRIGHT 2008 THOMSON REUTERS on STN
AN 2005-306268 [31] WPINDEX
DNC C2005-094925 [31]
TI Treating a joint condition, e.g. subchondral bone edema, comprises administration of an amino sugar formulation

DC B03
IN LOTZ M; OKUMU F W; SHIKHMAN A R; SHUE Y; OKUMU F; SHIKHMAN A
PA (OPTI-N) OPTIMER PHARM; (OPTI-N) OPTIMER PHARM INC; (SHUE-I) SHUE Y
CYC 107
PIA WO 2005034961 A1 20050421 (200531)* EN 36[7]
    EP 1670486   A1 20060621 (200643) EN
    JP 2007507516 W 20070329 (200725) JA 24
    US 20070142326 A1 20070621 (200741) EN
    CN 1909911   A 20070207 (200743) ZH
ADT WO 2005034961 A1 WO 2004-US32048 20040930; EP 1670486 A1 EP 2004-789289 20040930; EP 1670486 A1 WO 2004-US32048 20040930; JP 2007507516 W WO 2004-US32048 20040930; US 20070142326 A1 WO 2004-US32048 20040930; JP 2007507516 W JP 2006-534068 20040930; US 20070142326 A1 US 2006-574054 20060607; CN 1909911 A CN 2004-80032374 20040930
FDT EP 1670486   A1 Based on WO 2005034961 A; JP 2007507516 W Based on WO 2005034961 A
PRAI US 2003-507716P   20031001
    US 2006-574054   20060607
AN 2005-306268 [31] WPINDEX
AB WO 2005034961 A1 UPAB: 20051221
NOVELTY - Treating a joint condition comprises diagnosing a pathological marker associated with a joint condition and administering an amino sugar in a formulation.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for:

(1) treating synovitis, subchondral bone edema or cartilage degradation comprising administering an amino sugar;

(2) treating pathologies associated with a joint condition comprising administering N-acetylglucosamine as a controlled release formulation; and

(3) an injectable formulation comprising an aminosugar, which is entrapped by a matrix, where the matrix comprises a particle, implant or gel.

ACTIVITY - Osteopathic; Antiinflammatory.

Rabbits having bilateral anterior cruciate ligament transection (ACLT) were injected intra-articular injection of N-acetylgalactosamine (0.3 ml) (test compound) two times per week for a total of 7 weeks. Synovial fluid analysis was performed in animals that developed gross synovial effusions. The test compound showed improvement in the condition of the tibial plateaus and femoral condyles. The gross morphological analysis of the femoral condyles demonstrated a trend towards improved cartilage condition (improved lesions) (in terms of mild swelling) for the test group. The gross morphological analysis of the tibial plateaus revealed remarkable chondroprotective activity of the test compound (where 1 - 7 treatment rabbits developed a cartilage lesion) (in terms of mild effusion).

MECHANISM OF ACTION - None given.

USE - For the treatment of pathology associated with a joint condition which is not osteoarthritis, rheumatoid arthritis in a mammal e.g. synovitis, subchondral bond edema and cartilage degradation (all claimed).

ADVANTAGE - The formulation prevents cartilage degradation. The formulation prevents, lessen or reverse many of the pathological markers associated with joint conditions such as synovitis; provides improved biocompatibility and biodegradability.

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	383.25	383.46

FILE 'CAPLUS' ENTERED AT 17:57:44 ON 13 SEP 2008

FILE COVERS 1907 - 13 Sep 2008 VOL 149 ISS 12
FILE LAST UPDATED: 12 Sep 2008 (20080912/ED)

Caplus now includes complete International Patent Classification (IPC)
reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/legal/infopolicy.html

```
=> s Shue Youe-Kong/AU
L18         38 SHUE YOUE-KONG/AU

=> s l18 and aminosugar
           469 AMINOSUGAR
           308 AMINOSUGARS
           707 AMINOSUGAR
                 (AMINOSUGAR OR AMINOSUGARS)
L19          0 L18 AND AMINOSUGAR

=> s l18 and cartilage
         30097 CARTILAGE
          1202 CARTILAGES
         30304 CARTILAGE
                 (CARTILAGE OR CARTILAGES)
L20          2 L18 AND CARTILAGE

=> dis l20 1-2 bib abs

L20  ANSWER 1 OF 2  CAPLUS  COPYRIGHT 2008 ACS on STN
AN   2005:732530  CAPLUS
DN   143:166732
TI   Treatment of degenerative cartilage conditions in a mammal with
     glycosidase inhibitors
IN   Ichikawa, Yoshitaka; Shue, Youe-Kong; Orida, Norman K.; Lotz,
     Martin; Wong, Chi-Huey; Okumu, Franklin W.; Hwang, San-Bao
PA   Optimer Pharmaceuticals, Inc., USA
SO   PCT Int. Appl., 33 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     --------------      ----   --------    -------------------    --------
PI   WO 2005072268        A2    20050811    WO 2005-US2017         20050120
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
```

CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA	2553866	A1	20050811	CA 2005-2553866	20050120
EP	1713485	A2	20061025	EP 2005-706017	20050120
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
JP	2007518814	T	20070712	JP 2006-551318	20050120
US	20070197471	A1	20070823	US 2006-586578	20060925
PRAI US	2004-531168P	P	20040120		
	WO 2005-US2017	W	20050120		

AB The invention relates to treating, preventing, and lessening the severity of conditions selected from osteoarthritis, rheumatoid arthritis, synovitis, subchondral bone edema, and cartilage degradation with administration of glycosidase inhibitors. Compds. of the invention include e.g. hexosaminidase inhibitor (2R,3R,4R,5R)-N-methyl-2-(acetamidomethyl)-3,4-dihydroxy-5-(hydroxymethyl)pyrrolidine (OPT-66).

L20 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2005:346867 CAPLUS
DN 142:404290
TI Use of entrapped amino sugar compositions for treatment of synovitis, subchondral bone edema, and cartilage degradation
IN Shue, Youe-Kong; Okumu, Franklin W.; Shikhman, Alexander R.; Lotz, Martin
PA Optimer Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 36 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005034961	A1	20050421	WO 2004-US32048	20040930
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2540586	A1	20050421	CA 2004-2540586	20040930
	EP 1670486	A1	20060621	EP 2004-789289	20040930
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
	CN 1909911	A	20070207	CN 2004-80032374	20040930
	JP 2007507516	T	20070329	JP 2006-534068	20040930
	US 20070142326	A1	20070621	US 2006-574054	20060607
PRAI	US 2003-507716P	P	20031001		
	WO 2004-US32048	W	20040930		

AB The present invention relates to use of entrapped amino sugar compns. for

treatment of synovitis, subchondral bone edema, and cartilage degradation In particular, compns. comprising N-acetylglucosamine were administered intra-articularly or i.v. to rabbits with joint conditions.
RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> s Okumu Franklin W?/AU
L21 14 OKUMU FRANKLIN W?/AU

=> s l21 and aminosugar
469 AMINOSUGAR
308 AMINOSUGARS
707 AMINOSUGAR
(AMINOSUGAR OR AMINOSUGARS)
L22 1 L21 AND AMINOSUGAR

=> dis l22 bib abs

L22 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2005:493480 CAPLUS
DN 143:19991
TI Treatment of arthritis and other conditions in a mammal with administration of aminosugar compounds, and methods of use thereof
IN Ichikawa, Yoshitaka; Okumu, Franklin W.; Lotz, Martin
PA Optimer Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 60 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005051326	A2	20050609	WO 2004-US39680	20041123
	WO 2005051326	A3	20071011		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, AP, EA, EP, OA				
	CA 2546861	A1	20050609	CA 2004-2546861	20041123
	EP 1691779	A2	20060823	EP 2004-812241	20041123
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR, IS, YU				
	JP 2007525486	T	20070906	JP 2006-541445	20041123
	US 20070082851	A1	20070412	US 2006-580512	20060523
	CN 101141968	A	20080312	CN 2004-80036288	20060606
PRAI	US 2003-524698P	P	20031124		
	WO 2004-US39680	W	20041123		

OS MARPAT 143:19991
AB The invention discloses methods for treating, preventing, and lessening the severity of conditions or diseases selected from osteoarthritis, rheumatoid arthritis, synovitis, subchondral bone edema, and cartilage degradation by administration of an aminosugar derivative or

pharmaceutically acceptable salt thereof.

```
=> s Shikhaman Alexander R?/AU
L23          0 SHIKHAMAN ALEXANDER R?/AU

=> s Lotz Martin/AU
L24        129 LOTZ MARTIN/AU

=> s l24 and aminosugar
           469 AMINOSUGAR
           308 AMINOSUGARS
           707 AMINOSUGAR
                 (AMINOSUGAR OR AMINOSUGARS)
L25          1 L24 AND AMINOSUGAR

=> dis l25 bib abs

L25  ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2008 ACS on STN
AN   2005:493480  CAPLUS
DN   143:19991
TI   Treatment of arthritis and other conditions in a mammal with
     administration of aminosugar compounds, and methods of use
     thereof
IN   Ichikawa, Yoshitaka; Okumu, Franklin W.; Lotz, Martin
PA   Optimer Pharmaceuticals, Inc., USA
SO   PCT Int. Appl., 60 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     ---------------     ----   --------    --------------------   --------
PI   WO 2005051326        A2    20050609    WO 2004-US39680        20041123
     WO 2005051326        A3    20071011
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
             LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
             NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
             TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
             AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
             EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO,
             SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
             NE, SN, TD, TG, AP, EA, EP, OA
     CA 2546861           A1    20050609    CA 2004-2546861        20041123
     EP 1691779           A2    20060823    EP 2004-812241         20041123
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK,
             HR, IS, YU
     JP 2007525486         T     20070906    JP 2006-541445         20041123
     US 20070082851        A1    20070412    US 2006-580512         20060523
     CN 101141968          A     20080312    CN 2004-80036288       20060606
PRAI US 2003-524698P       P     20031124
     WO 2004-US39680       W     20041123
OS   MARPAT 143:19991
AB   The invention discloses methods for treating, preventing, and lessening
     the severity of conditions or diseases selected from osteoarthritis,
     rheumatoid arthritis, synovitis, subchondral bone edema, and cartilage
     degradation by administration of an aminosugar derivative or
     pharmaceutically acceptable salt thereof.
```

```
=> dis hist

     (FILE 'HOME' ENTERED AT 17:36:45 ON 13 SEP 2008)

     FILE 'APOLLIT, BABS, CAPLUS, CBNB, CIN, COMPENDEX, DISSABS, EMA, IFIPAT,
     NTIS, PASCAL, PROMT, RAPRA, SCISEARCH, TEXTILETECH, USPATFULL, USPATOLD,
     USPAT2, WPIFV, WPINDEX, WSCA, WTEXTILES, MEDLINE, EMBASE, BIOSIS' ENTERED
     AT 17:37:11 ON 13 SEP 2008
L1       126804 S GLUCOSAMINE OR N-ACETYL GLUCOSAMINE OR GALACTOSAMINE
L2        36190 S L1 AND (CARTILAGE(A)DEGRAD?) OR SYNOVITIS OR (SUBCHONDRAL(A)
L3        14398 S L2 AND TREAT?
L4         4305 S L3 AND (MATRIX OR PARTICLE OR GEL OR IMPLANT)
L5         1629 S L4 AND (ANTI(A)INFLAMMATORY(A)DRUG) OR HEXOAMINIDASE
L6          268 S L5 AND GLUCOSAMINE
L7            6 S L6 AND (SUBCHONDRAL(A)BONE(A)EDEMA)
L8          204 S L6 AND SYNOVITIS
L9         1371 S L5 AND SYNOVITIS
L10         305 S L9 AND INTRA(A)ARTICULAR
L11        1266 S L9 AND INJECT?
L12         295 S L10 AND INJECT?
L13      102103 S GLUCOSAMINE
L14         458 S L13 AND SYNOVITIS
L15         100 S L14 AND INTRA(A)ARTICULAR
L16          79 S L15 AND INJECT?
L17          73 S L16 AND (GEL OR IMPLANT OR MATRIX OR PARTICLE)

     FILE 'CAPLUS' ENTERED AT 17:57:44 ON 13 SEP 2008
L18          38 S SHUE YOUE-KONG/AU
L19           0 S L18 AND AMINOSUGAR
L20           2 S L18 AND CARTILAGE
L21          14 S OKUMU FRANKLIN W?/AU
L22           1 S L21 AND AMINOSUGAR
L23           0 S SHIKHAMAN ALEXANDER R?/AU
L24         129 S LOTZ MARTIN/AU
L25           1 S L24 AND AMINOSUGAR

=>

---Logging off of STN---



=>
Executing the logoff script...


=> LOG Y

COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                      31.48     414.94

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                      -3.20      -3.20

STN INTERNATIONAL LOGOFF AT 18:01:14 ON 13 SEP 2008
```